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Microglia are the resident macrophages of the central nervous system (CNS). In 
contrast to other members of the mononuclear phagocyte system, including other 
tissue macrophages as well as monocytes and dendritic cells, microglia exclusively 
derive from extra-embryonic yolk sac precursors during early embryonic 
development. Under steady state conditions microglia are long-lived and self-
maintain locally without the contribution of bone marrow-derived monocytes. As the 
innate immune cells of the CNS microglia present the first line of defense against 
invading pathogens and other damaging insults. In addition to their immune 
functions, microglia also play an essential role in maintaining CNS homeostasis for 
example by clearing cellular debris and supporting the proper formation and 
function of the neuronal network. Despite extensive research, there is still little 
known about the contributions of microglia to CNS pathologies. Evidence so far 
suggests that microglia play a dual role in these setting being able to support 
regeneration as well as further tissue destruction.  
In order to cope with the sensitive requirements of the CNS microglia harbor a 
unique genetic signature orchestrating their tissue-specific functions. Gene 
expression profiling has identified the transcriptional regulator Sall1 as one of the 
microglia signature genes. Sall1 is a zinc finger transcription factor originally 
identified in the proper organogenesis of limbs, kidneys, CNS and heart during 
embryonic development. Here we demonstrate that Sall1 is exclusively expressed 
by microglia within the hematopoietic system and the adult CNS. In contrast to 
previously described microglial markers, Sall1 is the first to specifically identify 
bona fide microglia and distinguish them from CNS-infiltrating monocyte-derived 
cells as well as from closely-related CNS-associated macrophages in the choroid 




By exploiting the Sall1 locus for inducible gene targeting in adult mice, we achieved 
a specific and highly efficient recombination in microglia under steady state 
conditions. Using this novel tool, we established a role for macrophage colony 
stimulating factor receptor (Csf-1R) in the maintenance of adult microglia. Given 
the dependence of microglia on Csf-1R signaling for their development, the 
importance of this pathway during microglia maintenance has long been proposed 
but never conclusively been demonstrated due to the draw backs of previous 
models. In contrast to that, we did not observe a crucial role for transforming 
growth factor beta receptor (TGF-βR) in microglia survival during steady state. Our 
data rather indicate that signaling via TGF-βR is important to suppress excessive 
activation of microglia. We further utilized the microglia-specific expression of Sall1 
to inducibly inactivate the Sall1 locus in vivo. This resulted in the transformation of 
microglia from ‘resting’ tissue macrophages into inflammatory phagocytes leading 
to disturbed tissue homeostasis and altered neurogenesis. Collectively, Sall1 
transcriptional regulation maintains microglia identity and physiological properties 





Mikroglia sind die lokalen Makrophagen des zentralen Nervensystems (ZNS) und 
somit gleichzeitig Bestandteil des mononukleären Phagozyten-Systems (MPS), 
welches sämtliche Gewebsmakrophagen sowie Monozyten und dendritischen 
Zellen umfasst. Im Gegensatz zu anderen Mitgliedern des MPS entstehen 
Mikroglia ausschließlich während der frühen Embryonalentwicklung aus extra-
embryonalen Dottersack-Vorläuferzellen. Unter homöostatischen Bedingungen 
sind Mikroglia langlebige Zellen, die sich lokal selbst regenerieren ohne den 
Einfluss von Monozyten aus dem Knochenmark. Mikroglia sind die angeborenen 
Immunzellen des ZNS und bilden die erste Verteidigungslinie gegen eindringende 
Krankheitserreger und andere schädliche Einflüsse. Zusätzlich zu ihren 
Immunfunktionen sind Mikroglia auch für die Aufrechterhaltung der ZNS-
Homöostase wichtig. Sie entfernen beispielsweise Überreste von abgestorbenen 
Zellen und tragen zur korrekten Bildung und Funktion des neuronalen Netzwerkes 
bei. Über die genauen Funktionen von Mikroglia bei verschiedenen Erkrankungen 
des ZNS ist trotz intensiver Forschung bisher nur bekannt. Man geht jedoch davon 
aus, dass sie eine duale Rolle spielen, die sowohl Regeneration als auch 
fortschreitende Schädigung des ZNS unterstützen kann. 
Um den sensiblen Anforderungen des ZNS gerecht zu werden, haben Mikroglia 
eine spezifische genetische Signatur, die es ihnen ermöglicht ihre 
gewebespezifischen Funktionen auszuüben. Die systematische Analyse von 
Genexpressionsprofilen hat ergeben, dass eines dieser mikroglia-spezifischen 
Gene der Transkriptionsregulator Sall1 ist. Sall1 ist ein so genannter Zink-Finger-
Transkriptionsfaktor, der ursprünglich während der Embryonalentwicklung im 
Zusammenhang mit der vollständigen Entwicklung von Gliedmaßen, Nieren, ZNS 
und Herz identifiziert wurde. Wir konnten in unserer Studie zeigen, dass Sall1 
innerhalb des hämatopoetischen Systems und des adulten ZNS ausschließlich von 
Mikroglia exprimiert wird. Im Gegensatz zu bisher beschriebenen Mikroglia-
Markern ist Sall1 der erste, der spezifisch für embryonal-entstandene Mikroglia ist. 
Er erlaubt ihre Unterscheidung sowohl von eingewanderten Monozyten aus dem 
Knochenmark, und draus hervorgehenden Zellen, als auch von den eng 
verwandten ZNS-assoziierten Makrophagen im Plexus choroideus, in den 
Hirnhäuten und in perivaskulären Bereichen. 
Zusammenfassung 
10 
Durch die Nutzung des Sall1-Lokus’ für induzierbare Genmanipulationen in 
erwachsenen Mäusen konnten wir Mikroglia spezifisch und effizient verändern. Mit 
Hilfe dieses neuen Systems konnten wir dem Zytokinrezeptor Csf-1R eine wichtige 
Funktion im Erhalt von Mikroglia während der Homöostase zuteilen. Nachdem 
bereits gezeigt wurde, dass die Entwicklung von Mikroglia von diesem Rezeptor 
abhängt, lag die Vermutung nahe, dass dieser auch für die Erhaltung der Zellen 
wichtig ist. Dies konnte bisher jedoch nicht abschießend gezeigt werden. Auch 
einem weiteren Zytokinrezeptor, TGF-βR, wurde eine wichtige Rolle in der 
Entwicklung von Mikroglia zugesprochen. Im Gegensatz zu Csf-1R, konnten wir für 
TGF-βR jedoch keine entscheidende Rolle im Erhalt von Mikroglia während der 
Homöostase beobachten. Unsere Daten zeigen jedoch, dass die 
Signalweiterleitung über TGF-βR wichtig ist, um eine übermäßige Aktivierung von 
Mikroglia zu unterdrücken. Darüber hinaus haben wir die Mikroglia-spezifische 
Expression von Sall1 verwendet, um den Sall1-Lokus in erwachsenen Mäusen zu 
inaktivieren. Diese Inaktivierung führte dazu, dass die „ruhenden“ 
Gewebsmakrophagen zu entzündlichen Phagozyten transformierten, was in einer 
gestörten Gewebshomöostase und in Veränderungen der Neurogenese resultierte. 
Zusammenfassend lässt sich sagen, dass die genetische Regulation von Mikroglia 
durch Sall1 die Identität und physiologischen Eigenschaften dieser wichtigen 






AA amino acid 
Ac acetylation 
AD Alzheimer’s disease 
Ahr aryl hydrocarbon receptor 
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AIRE autoimmune regulator gene 
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AM alveolar macrophages 
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Axl Tyrosine-protein kinase receptor UFO 
Aβ amyloid beta 
BBB blood brain barrier 
BCR B cell receptor  
BDNF brain-derived neurotrophic factor 
BM bone marrow 
C57BL/6 inbred mouse strain 
Ca calcium 
CCL2 CC-chemokine ligand 2 
CD cluster of differentiation 
cDC classical or conventional DC 
cDNA complementary DNA 
CFA  Complete Freund's Adjuvant 
CLR C-type lectin receptors 
cMoP common monocyte progenitor 
CNS central nervous system 
CNS-MF CNS-associated macrophages 
CO2 Carbon dioxide 
CP choroid plexus 
CpG 5'-C-phosphate-G-3' 
CreER tamoxifen-inducible Cre recombinase  
CSF cerebrospinal fluid 
Csf colony-stimulating factor 
Csf-1/ M-Csf macrophage colony stimulating factor 
Csf-1R macrophage colony stimulating factor receptor 




CX3CR1 fractalkine receptor 
Cxcl10 Interferon gamma-induced protein 10 (IP-10) 
Cybb cytochrome b subunit beta / NADPH oxidase 2 
Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 
D diversity gene 
DAMP damage-associated molecular pattern 
DAP12 DNAX-activating protein of 12 kDa 
DC dendritic cells 
DCX doublecortin 
ddH2O double-distilled water 
DNA deoxyribonucleic acid 
dNTP deoxy-nucleoside triphosphate 
dpp decapentaplegic 
DTT Dithiothreitol 
E embryonic day 
EAE experimental autoimmune encephalomyelitis 
EDTA Ethylenediaminetetraacetic acid 
EMP erythro-myeloid progenitors 
EpCam Epithelial cell adhesion molecule 
F4/80 EGF-like module-containing mucin-like hormone receptor-like 1 
FACS Fluorescence-activated cell sorting 
FCS fetal calf serum 
FLT3 FMS-like tyrosine kinase 3 
FLT3L FMS-like tyrosine kinase 3 ligand 
FMS Feline McDonough Sarcoma 
Foxp3 forkhead box protein 3 
G gauge (needle thickness) 
GFAP Glial fibrillary acidic protein 
GFP green fluorescent protein 
GLAST glutamate/ aspartate transporter 
H3K27Ac histone H3 lysine 27 acetylation 
H3K36me3 histone H3 lysine 36 trimethylation 
H3K4me3 histone H3 lysine 4 trimethylation 
H3K79me2 histone H3 lysine 79 dimethylation 
HBSS Hanks' Balanced Salt Solution 
HSC hematopoietic stem cells 
I-A/I-E murine MHC class two 
i.p intra peritoneal 
Iba-1 ionized calcium-binding adapter molecule 1 
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iDTR inducible Diphtheria Toxin Receptor 
Ifit Interferon Induced proteins with Tetratricopeptide repeats 
Ifitm3 Interferon Induced Transmembrane Protein 3 
IFN interferons 
Ig immunoglobulin 
Igf1 Insulin-like growth factor 1 
IHC immunohistochemistry 
IL interleukins 
ILC innate lymphoid cells  
Irf Interferon Regulatory Factor  
Itgal integrin alpha L chain 
iTregs adaptive or induced Tregs 
J joining gene 
kb kilo base pairs 
kDa kilo Dalton (protein size unit) 
KHCO3 Potassium bicarbonate 
LC Langerhans cells 
LPS lipopolysaccharide 
LRR leucine-rich repeat 
m meningeal 
M-MLV reverse transcriptase  
mAb monoclonal antibodies 
MAC membrane attack complex 
MALT mucosa-associated lymphoid tissues 
MAPK Mitogen-activated protein kinases 
MBL mannose binding lectin 
MBP Myelin basic protein 
MC monocyte-derived cells 
MDA5/ IFIH1 melanoma differentiation-associated protein 5 
Me methylation 
MerTK MER Proto-Oncogene Tyrosine Kinase 
MF macrophages 
Mg magnesium 
MHC major histocompatibility complex 
MoDC monocyte-derived dendritic cells 
MOG Myelin Oligodendrocyte Glycoprotein 
MPS mononuclear phagocyte system 
mRNA messenger RNA 
MS multiple sclerosis 
Msr1 Macrophage Scavenger Receptor 1 
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Mx1 Myxovirus Resistance 1 
NaOH sodium hydroxid 
ncRNA noncoding RNA 
NeuN Hexaribonucleotide Binding Protein-3 
NF-κB nuclear factor κB 
NGS next generation sequencing 
NH4Cl ammonium chloride 
NK natural killer 
NLR  NOD-like receptors 
NLRP Nod-like receptor protein 
NO nitric oxide 
NOD nucleotide-binding oligomerization domain 
NP neutrophils 
nTregs natural Tregs 
NuRD nucleosome remodeling and deacetylase 
o.g. oral gavage 
Olig2 oligodendrocyte transcription factor 2 
P phosphorylation 
P2ry12 purinergic receptor P2Y, G-protein coupled 12 
PAMP pathogen-associated molecular patterns 
PAP pulmonary alveolar proteinosis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pDCs plasmacytoid DCs 
PDGFR Platelet-derived growth factor receptor 
pHrodo pH-sensitive red dye 
PLO primary lymphoid organs 
PLX5622 Csf-1R inhibitor (Plexxikon) 
Pol II RNA polymerase two 
PPARγ peroxisome proliferator-activated receptor gamma 
PPR pattern recognition receptors 
ppt parts-per-trillion, 10-12 
pv perivascular 
PYD pyrin domain  
Q amino acid glutamine 
qPCR quantitative real-time PCR 
R26 Rosa26 locus 
RA retinoic acid 
RAG recombinase-activating gene 
RIG-I retinoic acid-inducible gene I 
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RLR RIG-I-like receptors 
RNA ribonucleic acid 
RNA-seq RNA-sequencing 
ROS reactive oxygen species 
rpm rotations per minute 
RT room temperature 
Runx1 Runt Related Transcription Factor 1 
S100B S100 calcium-binding protein B 
Sall spalt like gene 
SAS subarachnoid space 
Serpinf1 Pigment epithelium-derived factor 
SGZ subgranular zone 
Siglec Sialic acid binding Ig-like lectin 
Slc2a5 Solute Carrier Family 2 Member 5 
SLO secondary lymphoid organs 
Stard13 StAR-related lipid transfer domain protein 13 
Su sumoylation 
t-SNE t-Distributed Stochastic Neighbor Embedding 
TBS Townes-Brocks syndrome 
TCR T cell receptor 
TdT Terminal deoxynucleotidyl transferase 
TF transcription factor 
TGF-β Transforming growth factor beta 
TGF-βR Transforming growth factor beta receptor 
TLR Toll-like receptors 
TNFα Tumor necrosis factor alpha 
Tregs regulatory T cells 
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4.1 The immune system 
The mammalian immune system plays a central role in defending the host against 
various pathogens including bacteria, viruses and other parasites as well as 
harmful or toxic substances like allergens or venoms. It is divided into two arms 
namely the innate and the adaptive immune system, both of which have humoral 
and cellular components (Figure 1). Initially it has been thought that the innate and 
adaptive immune system act successive and independently of each other, however 
recent evidence shows a strong complementation and cooperation between the 
two branches of the immune system 1. 
In order to fully develop and function the immune system needs specialized 
structures, designated lymphoid tissues. These tissue structures can be divided 
into primary lymphoid organs (PLO), namely bone marrow (BM) and thymus, 
important for the development and maturation of immune cells and secondary 
lymphoid organs (SLO), including spleen, lymph nodes, tonsils, Peyer’s Patches 
and mucosa-associated lymphoid tissues (MALT). The main functions of SLO are 
to reduce the pathogen spread by strategically localized phagocytes, to facilitate 
effective interactions between different players of the immune system by bringing 
them in close proximity and to provide necessary factors for the differentiation and 
survival of lymphocytes. Furthermore, ectopic lymphoid aggregates at the site of 
infection can function as tertiary lymphoid organs harboring defined immune 
structures and memory cells 2. 
In addition to their role in immune protection, elements of the immune system also 




Figure 1 | The innate and adaptive immune response. The innate immune response functions as the first 
line of defense against infection. It consists of soluble factors, such as complement proteins, and diverse 
cellular components including granulocytes (basophils, eosinophils and neutrophils), mast cells, macrophages, 
dendritic cells and natural killer cells. The adaptive immune response is slower to develop, but manifests as 
increased antigenic specificity and memory. It consists of B cells, different T cells subsets including CD4+ and 
CD8+ T cells as well as regulatory T cells and antibodies as humoral components. In addition, natural killer T 
cells and γδ T cells are cytotoxic lymphocytes that straddle the interface of innate and adaptive immunity 
(adapted from 3). 
4.2 The innate immune system 
The innate immune system is comprised of physical, chemical and microbiological 
barriers, including epidermal surfaces, mucus or cilia that prevent pathogens from 
entering the body. In addition it harbors cellular effectors mainly of the myeloid 
lineage and serum components like the complement system and acute phase 
proteins. The innate immune system is highly conserved across different species 
and is characterized by a rapid response towards pathogenic agents based on the 
recognition of specific patterns 4.  
Innate immune cells are strategically positioned in many tissues and exert crucial 
functions in the initial response towards pathogenic insults and tissue injury 5. They 
are comprised by a multitude of cells from both the lymphoid lineage, like natural 
killer (NK) cells and innate lymphoid cells (ILC) as well as the myeloid lineage, 






























such as neutrophils (NP), basophils and eosinophils (Figure 1) 3. NK cells are 
armed with potent cytotoxic effector functions that are initiated based on integration 
of signals from activating and inhibitory receptors 6. Recognition of self major 
histocompatibility complex (MHC) class I is one of the main inhibitory signals, 
which makes NK cells potent killers of cells that down-regulate self-MHC-I due to 
viral infections or tumorigenic modifications 1. Neutrophils, macrophages and 
monocytes are the major phagocytic cells of the innate immune system, they 
engulf pathogenic microbes and destroy them in vesicles called phagolysosoms by 
toxic effector molecules, such as nitric oxide (NO), superoxide, and degradative 
enzymes. This process can be enhanced significantly by the opsonisation of the 
particles with complement molecules or specific antigens 1,4. With the uptake and 
processing of microbial antigens specialized antigen presenting cells (APC) like 
DCs, play a key role in adaptive immunity by presenting processed antigen 
peptides to T cells in a context of MHC molecules 1. Additionally innate immune 
cells modulate innate and adaptive immune responses by their secretion of specific 
immune-modulatory cytokines, like interleukins (IL), chemokines, colony-
stimulating factors (Csf) or interferons (IFN). 
As mentioned before innate immune cells are able to discriminate invading 
pathogens and damaged cells from commensal microorganisms and normal self 
using so-called pattern recognition receptors (PPR). Their recognition is based on 
conserved pathogen-associated molecular patterns (PAMP) or damage-associated 
molecular pattern (DAMP) respectively and is crucial for host defense and tissue 
remodeling 7. There are three main classes of PPRs, namely Toll-like receptors 
(TLR), RIG-I-like receptors (RLR) and NOD-like receptors (NLR), as well as C-type 
lectin receptors (CLR), AIM2-like receptors (ALR) and a family of enzymes 
functioning as intracellular sensors of nucleic acids all together covering the broad 
variety of molecular patterns 8. TLRs are expressed on the plasma membrane of 
innate immune cells and are able to recognize a wide range of extracellular 
pathogens. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are specialized to 
recognize components of bacterial and fungal cell walls, such as 
lipopolysaccharides (LPS), bacterial lipopeptides, flagellin or glycolipids. TLR3, 
TLR7, TLR8, TLR9 and TLR13 on the other hand are specialized on the 
recognition of viral nucleic acids in endosomal compartments such as CpG-DNA or 
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free single- or double-stranded RNA 9. Upon ligation of PAMPs to TLRs a signaling 
cascade centered around the nuclear factor κB (NF-κB) is initiated leading to the 
expression of pro-inflammatory cytokines and type I IFN 7. RLRs are a family of 
cytoplasmic RNA helicases important for the recognition and control of viruses 
including their replication and dissemination. Among those PPRs is the eponymous 
retinoic acid-inducible gene I (RIG-I) as wells as the melanoma differentiation-
associated protein 5 (MDA5; also known as IFIH1). Engagement of RLRs also 
results in the production of type I IFN 7. The third main group of PPRs, NLRs, are 
essential for host defense against bacterial infections. They are comprised of a 
large group of intracellular proteins including the nucleotide-binding oligomerization 
domain proteins (NODs) and NOD-, leucine-rich repeat (LRR) and pyrin domain 
(PYD)- containing proteins (NLRP) that recognize peptidoglycan motifs from 
bacterial cells, bacterial toxins or stress induced danger molecules like extracellular 
adenosine triphosphate ATP and uric acid crystals. NLR signaling also leads to the 
activation of NF-κB and Mitogen-activated protein kinases (MAPK) resulting in the 
production of pro-inflammatory cytokines. Furthermore by the activation of 
Caspase-1 NLRs are involved in the formation of so called inflammasomes 
inducing pro-inflammatory cascades 10. Even though the immune response initiated 
by PPRs is crucial for immediate host defense and the instruction of the adaptive 
immune system it needs to be tightly regulated in order to avoid excessive tissue 
damage and immunopathology. The regulatory network includes a multitude of 
enzymes, transcription factors and epigenetic molecules modulating distinct steps 
of the PPR signaling cascade in a cooperative or antagonistic manner 7. 
Apart from cell mediated responses serum factors also play a central role in innate 
immune reactions. Among those the complement system is the most prominent 
player comprising a complex network of more than 30 plasma and membrane-
associated serum proteins that induce highly efficient inflammatory and cytolytic 
immune responses 11. The complement proteins are organized in a hierarchy of 
proteolytic and assembly cascades that mount in the formation of a C3 convertase, 
cleaving the central complement component C3 into its active subunits (C3a, C3b). 
There are three types of complement activation pathways, namely the classical, 
the lectin and the alternative pathway depending on the initiating factor. While the 
classical pathway is activated by antigen-antibody complexes of the adaptive 
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immune response, the other two pathways are initiated by means of the innate 
immune defense. The lectin pathway hereby relies on the recognition of 
carbohydrates by PPRs like mannose binding lectin (MBL) or ficolins, whereas the 
alternative pathways is activated independently of PPRs by direct binding of C3 to 
hydroxyl or amine groups on the cell surface of microorganisms 12. Regardless of 
the initiation pathway, activation of the complement system converges to three 
main effector pathways. These include direct lysis of targeted surfaces by the 
assembly of the membrane attack complex (MAC), alerting and priming of the 
immune system by means of pro-inflammatory anaphylatoxins (C3a, C5a), and 
opsonization and clearance of target surfaces through recognition of complement 
opsonins (C4b, C3b, C3bi) by complement receptors on phagocytic cells, such as 
macrophages and neutrophils 11. 
4.3 The adaptive immune system 
The adaptive immune system is specific to higher animals and is characterized by 
a slower but much more specific immune response and the ability to form a long-
lived immune memory (Figure 1). Adaptive immunity is primarily based on the use 
of clonally diverse antigen-specific receptors on B and T cells. These receptors are 
encoded by genes that assemble through somatic DNA rearrangement and 
random chain pairing to permit the formation of millions of different antigen 
receptors 1. The effector response is divided into two steps, first the priming, 
activation and differentiation of the respective B or T cells after engagement with its 
specific antigen, which usually occurs within lymphoid tissues. And second, the 
effects that are mediated by the extravasation of activated T cells to the site of 
infection or the release of antibodies from activated B cells, so called plasma cells, 
into the blood and lymph system 4. 
T cells develop from a common lymphoid progenitor in the bone marrow that 
migrates to the thymus for further differentiation, thus the name T cell. There are 
two main classes of T cells, namely αβ and γδ T cells, depending on the T cell 
receptor (TCR) chains that are used, with the vast majority bearing an αβ TCR. 
Within specialized compartments of the thymus the individual chains of the TCR 
are assembled from variable (V), diversity (D) and joining (J) gene elements by 
somatic rearrangement to generate mature VJ α-chains and VDJ β-chains. The 
Introduction 
22 
assembly of these gene elements is initiated by the lymphoid-specific 
recombinase-activating gene (RAG) 1 and RAG 2 proteins, and further diversity is 
introduced by the insertion additional nucleotides into some of the VDJ junctions by 
the enzyme terminal deoxynucleotidyl transferase (TdT) 1. The TCR forms a 
complex with the co-signaling molecule CD3 and the thymocytes start to express 
the co-receptors CD8 and CD4 13. The CD4+CD8+ double-positive cells undergo 
positive selection in the thymic cortex to assure sufficient affinity of the TCR to self-
MHC molecules. During this step the immature T cells become single-positive in 
accordance with the MHC class they were selected on, namely CD4+ cells are 
restricted to antigen recognition via MHC-II while CD8+ cells are restricted to MHC-
I related antigen presentation. Another important regulatory step during T cell 
development is the negative selection in the thymic medulla, where pre-mature T 
cells are screened for auto-reactivity to tissue specific self-proteins under the 
control of the autoimmune regulator gene (AIRE) 1. More than 95% of immature T 
cells undergo apoptosis during thymic selection due to low MHC-affinity or auto-
reactivity. Both T cell linages exert distinct effector function, in general CD4+ T cells 
are designated T helper cells that activate both humoral and cellular immune 
responses by the production of cytokines, whereas CD8+ T cells possess cytotoxic 
activities against infected or tumorigenic cells 4. In addition to effector T cells a 
portion of CD4+ T cells are designated regulatory T cells (Tregs) that down-
regulate immune responses and maintain systemic tolerance. Tregs are 
characterized by the expression of the transcription factor (TF) forkhead box 
protein 3 (Foxp3), which is important for their development, and the surface marker 
CD25 (IL-2R). Two subsets of Tregs can be distinguished, namely the natural 
Tregs (nTregs), that develop their regulatory phenotype already in the thymus, 
while the adaptive or induced Tregs (iTregs) only differentiate in the periphery from 
naïve CD4+ T cells in the presence of IL-10, transforming growth factor β (TGF-β) 




B cells are bone-marrow derived lymphocytes that are defined by their production 
of immunoglobulin (Ig), which make up the B cell receptor (BCR) in a membrane-
bound form and are secreted as antibodies in a soluble form. Ig molecules are 
composed of two identical heavy (50 kDa) and light (25 kDa) chain pairs resulting 
in the formation of two identical antigen-binding site on each molecule. The 
assembly of the individual heavy and light chains occurs similar to that of TCRs by 
the somatic rearrangement of VJ (light chain) or VDJ (heavy chain) gene elements 
1. The variable region of each heavy and light chain pair is located at the amino-
terminal portion of the Ig molecule and creates the antigen-binding site. Each 
variable region includes 3 hypervariable sequences that allow for somatic 
mutations in the process of affinity maturation and clonal expansion of B cells in 
the germinal centers of secondary lymphoid tissues after immune activation 15. The 
carboxy-terminal portion of the heavy and light chains is constant within each 
antibody subclass. In line with that, the constant regions of the heavy chains form 
the Fc domain of the Ig molecule that exerts most of the effector functions, 
including Fc receptor engagement and complement activation 1. In a naïve state B 
cells only express IgM and IgD molecules. However upon immune activation, 
under the influence of helper T cells, isotype switching occurs by means of 
alternative splicing leading to a change in the constant region of the Ig molecule 
while the previously rearranged variable region and thereby the antigen specificity 
remains unchanged. This allows the B cell to produce antibodies with the same 
antigenic specificity but different effector functions 15. 
Both B and T lymphocytes are able to form long-lived memory cells that reside 
within the tissues and are able to mount a much faster adaptive immune response 




4.4 The mononuclear phagocyte system 
The mononuclear phagocyte system (MPS) represents one of the main cellular 
components of the innate immune system, including monocytes, macrophages and 
dendritic cells. Historically the MPS has been classified as a pool of functionally 
related myeloid cells that derive from a common progenitor in the bone marrow and 
are constantly replenished 16. This traditional view has been largely revised today 
appreciating ontogenic and functional differences between the individual cell 
subsets. Recent efforts have been made to imply a uniform nomenclature based 
on two levels, first the cellular origin and second the function, location and/or 
morphology (Figure 2) 17. A clear separation however remains challenging due to 




Figure 2 | Classification of mononuclear phagocytes. Mononuclear phagocytes can be defined on the basis 
of their ontogeny (level one nomenclature), followed by their function, location and/or morphology (level two 
nomenclature). This classification yields three main groups of cells namely, embryonic-derived macrophages, 
monocyte-derived cells and dendritic cells (DCs). Resident macrophages can be found in all body tissues and 
fulfil crucial homeostatic functions. They can be named either by location or historical discovery and depend on 
Csf-1R signaling for their development. Monocytes derive from BM precursors and are mainly found circulating 
in the blood stream. Upon inflammatory stimuli they can infiltrate body tissues and give rise to moncyte-derived 
cells (MC) with properties of macrophages and DCs. Bona fide DCs are dependent on Flt3 ligand for their 
development and can be further subdivided into ‘classical’ DCs (cDCs) and plasmacytoid DCs (pDCs) which 
arise from discrete committed precursors. Distinct DC subset are commonly distinguished by their location and 
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Monocytes have long been classified merely as the definitive precursors of MFs 
and some DCs despite their unique functions as mononuclear phagocytes 16. 
Nowadays they are appreciated as an individual cell lineage within the MPS based 
on their origin from a so-called common monocyte progenitor (cMoP) 18. Two 
subsets of monocytes can be distinguished namely the classical monocytes, 
characterized by their Ly6Chi (mouse) or CD14+CD16- (human) marker expression, 
and non-classical monocytes being Ly6Clow (mouse) or CD14lowCD16+ (human) 17. 
Classical monocytes can be found in the blood as well as in several tissues during 
steady state. They are the definitive precursors of several mononuclear 
phagocytes in adult tissues including gut, heart and dermis that rely on the 
constant replenishment by circulating monocytes. Most likely classical monocytes 
also give rise to the non-classical monocytes circulating and patrolling the blood 
vessels, even though this is still a matter of debate 19. 
Under inflammatory conditions there is a dramatic increase of classical monocytes 
in the inflamed tissues, which in turn differentiate to monocyte-derived cells (MC) 
including so called ‘inflammatory macrophages’ or ‘monocyte-derived DCs’ 
(MoDCs) with distinct phenotypes and functions depending on the environmental 
context. These include similarities to DCs, including migration to lymph nodes and 
activation of T cells, or to macrophages, including phagocytosis of pathogens and 
tissue repair, as well as immune-suppressive properties. Overall, monocyte-
derived cells are often highly heterogeneous even within one inflamed organ and 




DCs are considered the most specialized APCs as they express high levels of 
MHC-II on their surface to present processed antigens to T cells, prime those and 
initiate adaptive immune responses. In addition, DCs also promote peripheral 
tolerance during steady state conditions by capturing and presenting self-antigens 
and chronically found environmental proteins 20. Developing from a common DC 
progenitor in the bone marrow all DCs depend on the cytokine FMS-like tyrosine 
kinase 3 ligand (FLT3L) while additional specific transcription factors are required 
to form individual subsets. The three main subsets comprise two lineages of 
classical or conventional DCs (cDCs), namely cDC1 and cDC2, as well as 
plasmacytoid DCs (pDCs) (Figure 2).  
cDCs originate from an intermediate pre-cDC precursor that migrates from the BM 
to peripheral organs and differentiates locally into CD8a+ / CD103+ (mouse) or 
CD141+ (human) cDC1s or CD11b+ / CD172a+ (mouse) or CD1c+ (human) cDC2s 
that then reside in the tissue 17. In their immature state cDCs are highly phagocytic 
to take up antigens, process them and load them on MHC-II molecules within the 
lysosomal compartment. Upon maturation, cDCs lose some of their phagocytic 
activity and in turn increase their capacity to activate T cells by externalization of 
the antigen MHC-II complex together with the up-regulation of co-stimulatory 
molecules such as CD80 and CD86 and adhesion molecules 20. 
pDCs generally derive from committed pre-pDCs in the BM and are relatively long 
lived but only have a limited capacity to populate non lymphoid organs under 
steady-state conditions 21 22. As the name suggests pDCs morphologically 
resemble plasma cells and are less potent as APCs. However, in response to viral 
infections detected via TLRs pDCs characteristically release large amounts of type 




Tissue resident macrophages form the third entity of the MPS primarily being 
distinguished by their embryonic origin. In contrast to DCs that focus on initiating 
adaptive immune responses, the main function of macrophages is to ensure tissue 
homeostasis and integrity 22. In line with this, macrophages have a high phagocytic 
potential and degradative function to clear damaged cells, cell debris or foreign 
pathogens during innate immune responses. They are also able to present antigen 
to T cells via MHC-II molecules, however their priming capacity of T cells is much 
less efficient compared to that of DCs 22. In contrast to earlier concepts, it is now 
clear that the majority of tissue resident macrophages derive from embryonic 
precursors early during development. Several waves of hematopoietic precursors 
are produced in mammalian embryos that finally lead to the establishment of 
hematopoietic stem cells (HSC) in the BM 24. During the first wave around 
embryonic day (E) 7.5 to E8.0, extra embryonic yolk sac (YS) precursors initiate 
the primitive hematopoiesis by giving rise to erythro-myeloid progenitors (EMPs) 
that seed all embryonic tissues. In the so called aorta–gonad–mesonephros (AMG) 
region EMPs start to differentiate into pre-HSC and mature HSC that colonize the 
fetal liver around E10.5 and establish the definitive hematopoiesis 24,25. Even 
though EMPs seed all tissues, most tissue-resident macrophages, except microglia 
(discussed in detail below), are replaced by fetal liver monocytes during definitive 
hematopoiesis around E12.5 (Figure 3) 26. Once established tissue macrophages 
self-maintain locally and independently of circulating monocytes under steady-state 
conditions 27. In general, the development and survival of macrophages is highly 
dependent on the macrophage colony stimulating factor (M-Csf or Csf-1) receptor 
(Csf-1R). This has nicely been demonstrated in genetically-modified mice lacking 
Csf-1R, which show a grave reduction of macrophages throughout all body tissues 
resulting in severe developmental deficit including osteopetrosis and tooth eruption 
as well as reduced growth rate and increased postnatal mortality 28. In line with 
these findings, it was shown that Csf-1R can signal via two ligands namely Csf-1 
and IL-34, which have different contributions for the survival of individual 
macrophage populations 29. Given the vast diversity of body tissues and their 
distinct functional requirements, it is not surprising that macrophages are a very 
heterogeneous population 17. In addition to their general functions as immune 
sentinels each resident macrophage population acquires tailored functions 
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imprinted by the tissue microenvironment to cope with tissue-specific requirements 
30,31. In the recent years strong efforts have been made to identify the unique 
genetic signatures of individual macrophage populations to gain insights into their 
respective function and modulatory pathways 30-32. 
Langerhans cells (LC) in the epidermis of the skin are primarily derived from fetal 
liver monocytes with a small contribution from YS macrophages. They are recruited 
to the skin prior to birth and maintain locally in the skin throughout life under 
homeostatic conditions 22. Given their ontogeny and their development 
independently of FLT3L, they are classified here as macrophages even though 
they share many functional properties with cDCs. Similar to all macrophage 
populations, they rely on the signaling of Csf-1R for their development and 
maintenance. However, in contrast to many other macrophage populations, their 
development is independent of Csf-1 but requires IL-34-mediated Csf-1R signaling 
29. LCs represent the first barrier for skin invading pathogens, they are highly 
phagocytic and important for the cross-presentation of ingested antigens, while 
their ability to effectively prime T cells strongly depends on the respective 
pathogen. In addition they have a proposed role in allergenic contact 
hypersensitivity response 33. 
Similar to LCs, alveolar macrophages (AM) also derive from fetal liver monocytes 
that seed the fetal lung and fully mature during the first days after birth under the 
control of the granulocyte-macrophage colony stimulating factor (GM-Csf or Csf-2) 
and peroxisome proliferator-activated receptor gamma (PPARγ). They are located 
in the alveolar cavities and are crucial for lung development and homeostasis by 
clearing excess surfactant proteins and pathogens, apoptotic cells or allergens that 
are bound to these. Loss or dysfunction of AMs leads to the accumulation of 
surfactant and the subsequent development of pulmonary alveolar proteinosis 
(PAP)-like diseases 34. 
Liver-resident Kupffer cells and splenic red pulp macrophages share some 
prominent features related to their surveillance and filtering of the blood stream. 
They are required to clear senescent or damaged red blood cells and are crucial 
for iron homeostasis by recovering it through heme metabolization 35. This unique 
property is induced by the transcription factor Spi-C, which is also critical for the 
development of red pulp macrophages 36. Kupffer cells in addition regulate plasma 
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cholesterol levels by removing lipoproteins from the circulation and prevent 
systemic pathogen distribution by eliminating potentially harmful products such as 
microbial products, food antigens and xenobiotics 37. 
Furthermore, osteoclasts as fused multinucleated bone-resident macrophages are 
essential for normal long bone formation during embryogenesis and for bone 
resorption during the constant remodeling of this tissue 38. While embryonically 
derived peritoneal macrophages for example contribute to the IgA production of 
specialized peritoneal B cells 39. 
Of note, with regards to tumor development as a specific disruption of regular 
immune function, macrophages play a dual role. On one hand, they can counteract 
tumor formation by capturing and killing malignantly transformed cells. On the other 
hand, they can promote tumor growth by their ability to induce angiogenesis and 
increase immunosuppression 22. 
 
Figure 3 | Development of resident macrophages in different tissues. Several sources of myelopoiesis 
exist in the mouse. A transient early wave of myeloid cell development called primitive hematopoiesis takes 
place at embryonic day 7.5 (E7.5)–E8.0. At this time point, cells with stem cell properties develop in blood 
islands of the yolk sac (YS). Their progeny (erythro-myeloid progenitors (EMPs)) further differentiate into YS 
macrophages and populate several tissues, including the brain, where they become tissue macrophages that 
potentially have longevity and a high capacity for self-renewal. Shortly thereafter, myelopoiesis is taken over by 
progenitors found in the aorta–gonad–mesonephros region (not depicted) and fetal liver (starting at E12.5), 
where it forms part of the process of definitive hematopoiesis. Maturating myeloid cells derived from definitive 
hematopoiesis are engrafted in all tissues except the brain, where they at least partially replace the YS-derived 



































4.5 Immune privilege in the central nervous system 
The classical hallmarks of acute inflammation are calor (heat), rubor (redness), 
dolor (pain), tumor (swelling) and local loss of homeostatic tissue functions. These 
characteristics are the result of an active immune response including changes in 
vascular permeability, cell infiltration and release of immune mediating cytokines. 
Under normal conditions this does not affect vast body functions and tissue 
homeostasis is fully restored once the inflammation is resolved. For the central 
nervous system (CNS) even a temporary disturbance of the tissue homeostasis 
can have major impacts for the whole organism, which is why the CNS is relatively 
immune privileged. Similar exceptions are true for the eye, the placenta and the 
testes. In extension of earlier concepts it is now clear that this privilege is not 
absolute but demarcated to certain compartments and functions of the CNS 41. 
Widely spoken it includes the CNS parenchyma while border areas such as the 
meninges and the choroid plexus (CP) as well as the ventricles containing the 
cerebrospinal fluid (CSF) are omitted. A special structural feature supporting the 
separation of the CNS from the rest of the body is the blood brain barrier (BBB) 
(Figure 4). It is established by the neurovascular unit, which contains pericytes, 
astrocyte end feet and cerebral endothelial cells forming extremely firm tight 
junctions. It also contains a specialized basement membrane formed by 
extracellular matrix components and harbors unique membrane transporters 42. 
With regards to the immune response, it is mainly the afferent arm of the 
communication between the CNS and the immune system in the periphery that 
accounts for the privileged position 41. Even though recent studies have identified a 
lymphatic system in the CNS that allows the exchange of immune cells and fluid 
components between the CSF and the deep cervical lymph nodes 43, the 
communication between CNS and periphery is still tightly controlled. The 
emigration of APCs to the draining lymph nodes is widely reduced and these cells 
accumulate in the inflamed CNS. Furthermore, soluble antigens that drain along 
perivascular spaces and the subarachnoid space (SAS) into the cervical lymph 
nodes fail to elicit effective cytotoxic T cell responses or delayed-type 
hypersensitivity. In contrast, they rather skew the immune effects towards a 
humoral or T helper type-2 response and even induce tolerizing effects 41. In 
addition, the efferent arm of the immune response in the CNS is also specialized. 
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Even though effector cells can reach the CSF and the CNS border areas through 
the cervical lymph nodes and the CNS lymphatic system 43, their entry into the 
parenchyma is tightly regulated by the BBB. Once in the CNS, entering T cells for 
example face a rather pro-apoptotic and anti-inflammatory environment 
characterized among others by the elevated expression of the apoptosis inducing 
Fas ligand on CNS resident cells and the high levels of TGF-β inducing the 
conversion of effector T cells to Tregs 41. Furthermore, also the innate immune 
system of the CNS is very unique being dominated by microglia as the CNS-
resident tissue macrophages (discussed in detail below). 
 
 
Figure 4 | Cerebral microcirculation and the neurovascular unit. In the brain, pial arteries run through the 
subarachnoid space (SAS), which contains the cerebrospinal fluid (CSF). These vessels give rise to 
intracerebral arteries, which penetrate into brain parenchyma and branch into smaller arteries and 
subsequently arterioles. Intracerebral arteries are separated from brain parenchyma by the pia, the innermost 
layer of the meninges, and the astrocyte end feet. At the brain capillary level, vascular endothelial cells and 
pericytes are attached to the basement membrane. Pericyte processes encase most of the capillary wall, and 
they communicate with endothelial cells directly through synapse-like contacts. Astrocyte end-foot processes 



























4.6.1 Origin and development 
Microglia have first been described and named by del Río-Hortega in the 1930s as 
a small population of phagocytic and migratory cells in the brain that are distinct 
from neurons and macroglia such as astrocytes and oligodendrocytes. Despite 
extensive research the origin and development of microglia has only been 
discovered in the recent years (Figure 5). The first wave of hematopoietic 
precursors originates from the extra-embryonic yolk sac blood islands around E7.5 
and induces the primitive hematopoiesis 24. During that time c-kit+ erythro-myeloid 
precursors (EMPs) give rise to primitive yolk sac macrophages that seed the brain 
rudiment through developing blood vessels around E9.5 45,46. The generation these 
early microglia precursors is dependent on Runt Related Transcription Factor 1 
(Runx1) 47,48. Upon homing to the brain these primitive macrophage develop into 
CNS resident microglia that show a mature, ramified phenotype as early as E14 45. 
Similar to other macrophages, the development of microglia is strongly dependent 
on Csf-1R signaling which can be induced by either ligand Csf-1 or IL-34 46. 
Additionally, the myeloid-specific factor PU.1 (encoded by Spi1) and its interaction 
partner Interferon Regulatory Factor 8 (Irf8) have also been shown to be crucial for 
the development of microglia 45. While the transcription factor Myb, required during 
definitive hematopoiesis, is dispensable for yolk sac derived macrophages 49. 
Recent studies also propose a critical role for TGF-β in microglia development 50. 
The exact contribution however needs to be verified in more detail. 
Under physiological conditions CNS-resident microglia are long-lived, can resist γ-
irradiation and maintain themselves locally without any contribution of fetal liver or 
BM derived monocytes 46. Furthermore, different mouse models have shown that 
depletion of microglia leads to a rapid repopulation of the empty niche until normal 
microglial numbers are re-established. This repopulation is driven by CNS-intrinsic 
sources and microglia themselves show a high proliferative capacity 51. Under 
certain conditions involving BBB disruption due to irradiation or injury, microglia 
can also be repopulated by BM-derived cells upon depletion. Even though these 
cells to some extend acquire a microglia phenotype and function, the genetic 
profile of BM-derived ‘microglia-like’ cells differs from that of embryonically-derived 
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microglia. It remains to be shown if newly engrafted BM-derived cells can maintain 
the ‘microglia’ pool over an extended period of time and fully acquire the 
characteristics of embryonically-derived microglia, including steady state functions 
and self-maintenance 51. 
 
 
Figure 5 | Schematic for the development of microglia. During primitive hematopoiesis around E7.5 
erythro-myeloid precursors (EMPs) give rise to yolk sac (YS) macrophages that seed the brain rudiment 
through developing blood vessels around E9.5. The generation of EMPs is dependent on Runt Related 
Transcription Factor 1 (Runx1) while the further development into mature microglia is strongly dependent on 
the myeloid-specific factor PU.1 and its interaction partner Interferon Regulatory Factor 8 (Irf8) as well as 
on colony stimulating factor 1 receptor (Csf-1R) and transforming growth factor beta (TGF-β) signaling. Under 
steady state conditions microglia have the capacity to self-renew and maintain locally without the contribution 
of circulating monocytes.  
4.6.2 Other CNS resident myeloid cells 
Apart from microglia located in the CNS parenchyma, additional CNS-associated 
macrophages (CNS-MF) can be found at the CNS borders namely the perivascular 
(pv) space, the meninges and the choroid plexus (CP). Recent studies have shown 
that these border areas are also seeded early during embryonic development by 
macrophage progenitors 52, even though the specific origin of these progenitors 
from YS or fetal liver remains to be identified. Similar to microglia, the development 
of CNS-MF is highly dependent on Csf1r and PU.1 but independent of Myb. In 
addition, genetic deletion of Ifr8 resulted in a reduction of meningeal MFs (mMF) 
while the numbers of CP MF remained unchanged indicating distinct dependences 
52. Along the same lines, fate mapping studies showed that pvMF and mMF retain 
their embryonic origin throughout adulthood whereas CP MF were replaced over 














unlike microglia all CNS-MF are sensitive to γ-irradiation and also display a more 
amoeboid morphology 52. The different contributions of microglia and CNS-MF to 




Figure 6 | Myeloid cell types in the CNS. Under homeostatic conditions, the brain hosts several 
heterogeneous populations of myeloid cells that are located at distinct sites, where they execute homeostatic 
and surveillance tasks. Within the brain parenchyma, microglia with small delineated processes actively screen 
the intraneuronal space for incoming threats, whereas macrophages can be found in the outer boundaries of 
the brain, such as the choroid plexus, perivascular space, and in the meninges. DCs are present at low 


















4.6.3 Homeostatic functions 
Despite intensive investigations it remains difficult to properly define the 
homeostatic functions of microglia within the CNS. Doubtlessly they are the local 
innate immune cells and represent the first line of defense against invading 
pathogens and damaging insults. Microglia constantly scan the CNS parenchyma 
with their highly motile processes and clear cellular debris and accumulated 
products to restore tissue homeostasis 53. In addition to their immune functions, it 
has been shown that microglia play a key role during brain development and 
proper formation of neuronal circuits by a process called synaptic pruning and the 
engulfment of synaptic material as well as apoptotic neurons 54. Even more so, in 
the cerebellum microglia can actively induce apoptosis of developing Purkinje 
neurons by so called respiratory burst that is characterized by the rapid release of 
reactive oxygen species (ROS) 55. A transient reduction of microglia numbers 
and/or decreased recognition of synapses before and during engulfment e.g. by 
the depletion of the fractalkine receptor (CX3CR1) results in an excess of dendritic 
spines and an increase in synaptic release sites indicative of immature synapses 
54. Along those lines, mice lacking CX3CR1 show abnormalities in social 
interactions and repetitive behaviors as a result of neurodevelopmental changes 56. 
The cytokine receptor CX3CR1 on the cell surface of microglia represents one of 
the main interaction pathways between microglia and neurons. Under physiological 
conditions CX3CR1 responds to its ligand fractalkine (CX3CL1) mainly produced by 
neurons to restrain microglia activity and maintain their surveying phenotype 57. 
Similar crosstalk to inhibit excessive microglia activation is established through the 
CD200R – CD200, CD172 – CD47 and CD45 – CD22 axes, in which microglia 
always carry the receptors for the respective neuronal ligands 58. In addition to 
cellular interactions, soluble factors secreted by microglia critically influence 
neuronal development and function. Among those brain-derived neurotrophic factor 
(BDNF) is one of the best studied so far and has been shown to modulate neuronal 
plasticity, synaptic remodeling and neurotransmission especially in glutamatergic 
neurons assigning an important role during learning and memory formation to 
microglia 59. Interestingly the crosstalk between neurons and microglia is not one-
directional but neurons also tune microglia activities by means of their own activity 
levels, the response to visual stimuli and the strength of their synapses 60,61. 
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Furthermore, recent evidence suggests that microglia are crucially involved in adult 
neurogenesis in the subgranular zone (SGZ) of the hippocampus by phagocytosis 
of excessively generated, apoptotic neurons without promoting inflammation 62. In 
fact, it has been shown that pro-inflammatory stimuli have a negative impact on 
neurogenesis 63. 
4.6.4 Role during neuroinflammation 
Upon inflammatory stimuli microglia change their gene expression profile and 
phenotypic appearance, morphologically indicated by switch from a ramified cell 
body with long, dynamic processes and a small cell soma to a rather amoeboid 
phenotype. With regards to neurodegenerative diseases such as Alzheimer’s 
disease (AD) and multiple sclerosis (MS) as well as aging, activation of microglia 
may lead to both protective but also pathogenic effects. Protective functions of 
microglia include phagocytosis of cellular debris, secretion of growth factors and 
initiation of regenerative processes to restore tissue homeostasis 64. In contrast, 
promotion of pathogenic microglia functions result in the production of neurotoxic 
factors such as ROS or NO as well as the release of pro-inflammatory cytokines 
and chemokines including IL-1β, tumor necrosis factor alpha (TNFα) and CCL2 
(Figure 7). These immune mediators may lead to the activation of astrocytes 
resulting in astrogliosis and promote the infiltration of BM-derived monocytes into 
the CNS parenchyma that differentiate into effector cells, such as monocyte-
derived MF or DCs 64. Additionally, several mutations in genes related to microglia 
function including DNAX-activating protein of 12 kDa (DAP12) mediating synaptic 
signaling via BDNF and the PRRs triggering receptor expressed on myeloid cells 2 
(TREM2) promoting phagocytosis or Nod-like receptor protein 3 (NLRP3) forming 
the inflammasome have been proposed to correlate to the pathogenesis of 
neurodegenerative diseases 65. 
CNS demyelination such as in MS and the related mouse model experimental 
autoimmune encephalomyelitis (EAE), is mainly initiated by the infiltration of 
autoreactive CD4+ T cells 66. However, the effector mechanisms leading to disease 
progression are provided by CNS-resident microglia and infiltrating monocyte-
derived cells. These myeloid cells promote the encephalitogenic potential of 
infiltrating T cells by the secretion of pro-inflammatory cytokines such as IL-12 and 
Introduction 
37 
IL-23 67,68. Furthermore, they produce chemokines, attracting additional effector 
cells from the periphery, and ROS, increasing the neuronal damage 69. Recent 
studies claim that it is mainly the infiltrating monocyte-derived MF that are highly 
activated and have a strong disease promoting effect by initiating demyelination 
preferably at the nodes of Ranvier 70. Whereas the resident microglia show a rather 
repressed gene expression profile, appear relatively inert and merely clear debris 
of damaged neurons 70. More studies will be needed to clearly decipher the 
differential roles of resident microglia vs. CNS-associated myeloid cells or 
infiltrating myeloid-derived cells. A similar pattern seems to be true for models of 
amyotrophic lateral sclerosis (ALS) where the progressive recruitment of 
monocytes to the spinal cord promotes neuronal loss. Interestingly this recruitment 
seems to be mediated by microglia producing the chemoattractant CCL2 while they 
themselves succumb to apoptosis with advanced disease progression 71. 
One of the characteristics of AD is the deposition and aggregation of amyloid β 
(Aβ). It has been shown that Ly6Clow monocytes patrolling the blood vessels and 
pvMF located at the borders are able to clear Aβ from these sites and reduce the 
plaque burden in the CNS 72,73. The role of microglia in the clearance of Aβ plaques 
is more controversial. Even though microglia are initially able to engulf deposited 
Aβ, increasing plaque burden in the CNS seems to inhibit their phagocytic capacity 
and the motility of their processes towards the site of deposition. Along the same 
lines, transient depletion of microglia in murine AD models did not rescue plaque 
burden or neuritic dystrophy 74. Moreover, in vitro studies suggest that microglia 





Figure 7 | Activated microglia in neurodegenerative disease. Various disease-associated factors can 
activate microglia through pattern-recognition and purinergic receptors to establish an activated phenotype. 
Such factors include, damage-associated molecular patterns (DAMPs; such as high-mobility group box 1 
protein (HMGB1), histones and ATP), as well as neurodegenerative disease-specific protein aggregates (such 
amyloid-β). Pro-inflammatory mediators produced by activated microglia activate astrocytes, and the products 
released by activated microglia and astrocytes may exert neurotoxic effects. Activated astrocytes also release 
cytokines, including colony-stimulating factor 1 (Csf-1) and tumor necrosis factor (TNF), that further induce the 
activation and proliferation of microglia. Communication between microglia and astrocytes may therefore 
amplify pro-inflammatory signals initially sensed by microglia and contribute to the pathology of 
neurodegenerative disease. (adapted from 64) 
 
Also for acute CNS injury it has been shown that monocyte-derived MF infiltrating 
the CNS promote functional recovery 77. Contradicting studies however claim 
detrimental roles for infiltrating monocytes during spinal cord injury. One 
explanation for this discrepancy could be that the role of infiltrating cells depends 
on the time point and/or port of CNS entry, which seems to promote either a pro- or 
anti-inflammatory phenotype 77. Similarly, microglia that accumulate in the core of 
the lesion and the surrounding penumbra play dual roles by contributing to the 
demise of neurons and exacerbation of the lesion size through synthesis of pro-
inflammatory mediators on the one hand. And on the other hand forming the 
prerequisite for synaptic regeneration by scavenging cellular debris 78. 
ββ
surveilling microglia activated microglia
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In addition to disease settings, aging has an important influence on microglia 
function and CNS homeostasis as it is characterized by increased oxidative stress 
and low-grade inflammation 79. Aged microglia display a more activated phenotype 
indicated by morphological changes and constitutive secretion of TNFα and IL-6. 
Furthermore, a decline in lysosomal and mitochondrial functions in microglia during 
aging results in the excessive generation of ROS and an increased cytokine 
response to insults 80. 
Taken together, these examples show that microglia, CNS-associated MF and 
monocyte-derived cells play distinct, non-redundant roles in settings of CNS injury 
and degeneration. These functions are highly regulated and can be both 
detrimental and protective depending on the specific inputs. Further studies will be 
needed to fully understand the underlying mechanisms regulating myeloid cell 
functions in the CNS and to allow for beneficial manipulation. 
4.7 Transcription factors and genetic regulation 
Genetic regulation is the most fundamental ways of inducing, controlling, regulating 
and coordinating all processes in the body. Even though it follows similar concepts, 
genetic regulation varies between species, individuals and even single cells. 
Exemplarily, this becomes clear with regards to the previously mentioned 
differences between individual tissue resident macrophage populations, where the 
specific identity and function is imprinted by a unique genetic signature 30-32. In 
contrast to functional specialization, alterations in the genetic signature e.g. by 
mutations in regulatory sequences or transcriptions factors can also be the cause 





4.8 Concepts of gene regulation 
The deoxyribonucleic acid (DNA) consists of a huge variety of genes that are 
transcribed into protein-coding and noncoding ribonucleic acid (RNA). The protein-
coding RNA, encoded on exon sequences, will be translated into amino acid (AA) 
sequences by ribosomes, which undergo further post-translational modifications 
before they finally get folded into functional proteins. Each step of this protein 
biosynthesis pathway is tightly regulated and the main concepts of this regulation 
on a genetic level will be described as follows. 
Transcriptional regulation generally occurs on two interconnected levels, namely 
transcription factors and the transcriptional apparatus itself, as wells as on the 
chromatin level including the DNA-packaging histones (Figure 8) 81.  
Transcription factors (TF) form a complex network of genetic regulations and can 
be divided into initiation or elongation controlling elements with most TF 
contributing to transcription initiation. They typically bind to enhancer elements in 
the promoter regions of genes together with other TF and recruited cofactors in a 
cooperative fashion. The cofactors have modulating functions themselves and can 
be either activating or repressive but they are unable to bind DNA directly. For 
each TF complex located to the core promoter region of a gene, all inputs of the 
individual participants will be combined and define the regulatory outcome on the 
initiation of the DNA transcription by the enzyme RNA polymerase II (Pol II). After 
transcribing a short distance Pol II is stopped by pause control factors and 
additional TF are required to release Pol II from these pause sites 81.  
The second level of modulation is related to the basic chromatin unit, the 
nucleosome that consists of a DNA segment wrapped around a core of eight 
histone proteins. Chromatin remodeling processes, partially induced by TF, lead to 
the mobilization and accessibility of nucleosomes and the recruitment of histone 
modifying enzymes resulting in an open euchromatin vs. condensed 
heterochromatin structure. Common histone modifications are acetylation, 
methylation and ubiqutinylation, which are induced and removed in a highly 
dynamic fashion. The activation state of a specific gene can be identified by its 
characteristic chromatin modifications, which allows the differentiation not only 
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between active and repressed genes but also between genes that are temporary 
repressed but poised for later activation and those that are fully silenced 81. 
In addition to the two major levels of transcriptional modulation there is also 
noncoding RNA (ncRNA) that is usually transcribed from intron sequences of 
genes. ncRNA contributes to the control of gene expression through the 
modulation of transcriptional and post-transcriptional processes. There are different 
classes of ncRNA, the best studied one being microRNAs, which are only about 22 
nucleotides of length and modulate gene expression at the level of messenger 
RNA (mRNA). Additionally, there are long ncRNAs with contribute to transcriptional 
modulation by recruitment of chromatin regulators 81. Furthermore, so-called 
enhancers are genetic elements that increase the transcription of genes 
independent of their orientation and distance relative to the promoter region. They 
can be located within intron sequences of the same gene, several kilo base pairs 
(kb) upstream or downstream of the promoter and due to chromosome pairing 
even on a different chromosome 82. 
 




(A) Formation of a pre-initiation complex. Transcription factors bind to specific DNA elements (enhancers) and 
to co-activators, which bind to RNA polymerase II, which in turn binds to general transcription factors at the 
transcription start site (arrow). The DNA loop formed between the enhancer and the start site is stabilized by 
cofactors such as the Mediator complex and cohesin. (B) Initiation and pausing by RNA polymerase II. RNA 
polymerase II begins transcription from the initiation site, but pause control factors cause it to stall some tens of 
base pairs downstream. (C) Pause release and elongation. Various transcription factors and cofactors recruit 
elongation factors, which phosphorylates the pause release factors and polymerase, allowing elongation to 
proceed. (D) Chromatin structure is regulated by adenosine triphosphate (ATP)-dependent remodeling 
complexes that can mobilize the nucleosome, allowing regulators and the transcription apparatus increased 
access to DNA sequences. (E) Transcriptional activity is influenced by proteins that modify and bind the 
histone components of nucleosomes. Some proteins add modifications (writers), some remove modifications 
(erasers), and others bind via these modifications (readers). The modifications include acetylation (Ac), 
methylation (Me), phosphorylation (P), sumoylation (Su), and ubiquitination (Ub). (F) Histone modifications 
occur in characteristic patterns associated with different transcriptional activities. As an example, the 
characteristic patterns observed at actively transcribed genes are shown for histone H3 lysine 27 acetylation 
(H3K27Ac), histone H3 lysine 4 trimethylation (H3K4me3), histone H3 lysine 79 dimethylation (H3K79me2), 
and histone H3 lysine 36 trimethylation (H3K36me3). 81 
4.9 Zinc finger transcription factor Sall1 
As mentioned before, tissue-specific identity of macrophages is tightly regulated by 
unique signature genes throughout development and adulthood. Regarding 
microglia, several signature genes have recently been proposed, among those 
Sall1 32,50,70,83,84. 
Sall1 is one of the four murine members of the spalt (spalt like, Sall) genes, that 
have originally been identified in Drosophila and are evolutionarily highly 
conserved from C. elegans to vertebrates 85. Spalt genes are a family of zinc finger 
transcription factors carrying several conserved zinc finger domains mostly 
clustered in duplex or triplets as well as a glutamine-rich (polyQ) region (Figure 9). 
The exact functions of individual domains remain to be established, some are 
probably involved in DNA binding while others account for protein-protein 
interactions and transactivation 86. Sall1 for example has been shown to mediate 
transcriptional repression by the recruitment of the nucleosome remodeling and 
deacetylase (NuRD) complex 87. In contrast to that Sall1 has also been shown to 
synergistically activate canonical, β-catenin-dependent Wnt-signaling via binding to 
heterochromatin within the cell nucleus and altering its structure 88. This could 
imply a role of Sall1 in Wnt-related processes such as embryogenesis but also 
cancer development. In addition to transcriptional regulations Sall1 might also be 
involved in post-translational modifications by modulating sumoylation of proteins. 
Sumoylation, in contrast to the closely related process of ubiquitinylation, does not 
Introduction 
43 
mark proteins for degradation but rather alters protein affinity, localization or 
function and possibly even protects from ubiquitin-mediated proteolysis 89. 
 
 
Figure 9 | Schematic representation of the main conserved domains present in Sall proteins. Colored 
ovals numbered 1 to 5 represent the zinc finger domains from vertebrate Sall homologues. White rectangles 
represent the poly-glutamine regions. The arrow in Sall1 indicates the sumoylation site described for this 
protein. Colored horizontal bars below each protein indicate the Sall-interaction domains with other proteins. 
Vertebrate data were collected from human, mouse, chicken and frog homologues. (adapted from 90) 
 
As already indicated, spalt genes have been shown to play a crucial role during 
embryogenesis where they are required for the normal development of different 
organ systems including limbs, kidney, CNS and heart. Even though very little is 
known about the exact regulations and interactions of spalt genes, a common 
concept is the involvement in patterning and co-ordination during organogenesis. 
This has been nicely demonstrated for the kidney where Sall1 is essential for uteric 
bud invasion as the initial step of metanephros development 86. In the developing 
embryo Sall1 is expressed in the metanephric mesenchyme surrounding the uteric 
bud and induces its outgrowth into the adjacent tissue. Reciprocal interaction of 
both tissues and branching of the uteric bud induces tubule formation and forms 
the basis for normal kidney development. In Sall1 knockout mice the key inducing 
signal is missing, which eventually leads to the apoptosis of the mesenchyme and 
the mice die within the first 24h after birth due to severe kidney dysgenesis or 
agenesis 86. Similar to the kidney, Sall1 also seems to take over crucial inducer 
functions during limb and heart development 85. Spalt genes are also expressed 
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during CNS development across species. In mice Sall1 shows a robust expression 
in early progenitor cells and promotes terminal neurogenesis 91. In the cerebral 
cortex this is achieved first by the generation of radial glial cells from symmetric 
division of progenitor cells and later by the asymmetric division of these radial glial 
cells into intermediate progenitors that ultimately give rise to mature neurons. Sall1 
seems to regulate all these steps preferentially promoting proliferation over 
differentiation 91. Further investigations are needed to elucidate the spatio-temporal 
regulation of Sall1 and other spalt genes to better understand their role in tissue 
development and patterning. 
4.10 SALL1-deficiencies in human 
In humans, heterozygous mutations of SALL1 lead to Townes-Brocks syndrome 
(TBS), an autosomal dominant developmental disorder. Characteristic features of 
TBS are anomalies of hand and feet, anorectal abnormalities, deformities of the 
outer ear, along with hearing impairments and in several cases also malformations 
of the kidney. Less common symptoms can also be heart anomalies and mental 
retardation 92. These symptoms, especially the kidney phenotype, correlate to 
some extend to what has been observed in mice 86. The mutations of the SALL1 
gene leading to TBS often cause a premature stop codon in the gene sequence 
terminating the transcription before the functionally relevant zinc finger domains. 
Furthermore, the truncated SALL1 protein interferes in a dominant-negative 
manner with the function of its full-length counterpart, rendering both proteins 
unfunctional 85. In contrast to TBS, homozygous, autosomal recessive mutations in 
SALL1 can lead to ‘multiple congenital anomaly–mental retardation syndrome’, 
characterized by prenatal onset of chronic renal failure and severe CNS 
involvement 93. As indicated earlier, SALL1 could also play a role in tumorigenesis 
by its ability to enhance Wnt signaling and has been reported at high levels in 
Wilms tumor 85. Firm evidence for these implications is still missing and given the 




5 Specific Aims 
Microglia are the resident macrophages of the central nervous system. In addition 
to their function as innate immune cells in this immune privileged organ, microglia 
also play a crucial role in tissue homeostasis and during inflammation. Despite 
intensive research over the past decades, their exact contributions remain to be 
defined. One of the reasons that our understanding of microglia biology is still 
relatively limited is the fact that conditional gene-targeting of microglia often leads 
to inadvertent targeting of other members of the mononuclear phagocyte system, 
including monocytes and macrophages. Recent efforts have been made to identify 
unique signature genes of individual resident tissue macrophage populations. In 
line with this the transcription factor Sall1 has been proposed to be specifically high 
expressed in microglia compared to other MPS members. Within the scope of this 
thesis the following aims will be addressed: 
 
We want to verify that Sall1 is specifically expressed by microglia but not by 
any other member of the MPS or hematopoietic system. 
 
Utilizing the tamoxifen-inducible Sall1CreER mouse strain, we aim to modulate and 
target microglia in vivo. 
 
Establishing this novel targeting scheme, our goal is to exploit Sall1 to better 
understand microglia biology and function under different conditions. 
 
Given the high expression levels of Sall1 in microglia, we aim to determine the 









6.1 Microglia-specific expression of Sall1 
Microglia are the resident tissue macrophages of the CNS and pose a specialized 
sub-population of the MPS 94. Given their highly specialized functions depending 
on the tissue environment they reside in, each macrophage subset has a unique 
gene expression signature. In the case of microglia this signature includes several 
transcription factors, among them Sall1 32. In order to validate that Sall1 was 
specifically expressed by microglia but not by other members of the hematopoietic 
system, we used Sall1GFP/+ reporter mice 95. Using flow cytometry, we analyzed the 
CNS of Sall1GFP/+ mice where we detected a population of GFP+ cells among the 
CD45+ cells, which corresponded to microglia, characterized as CD45loCD11b+ 
cells. Furthermore, by gating first on microglia we could show that all of these cells 
express GFP (Figure 10a). To investigate whether other hematopoietic cells also 
express Sall1 we sorted different leukocyte populations from peritoneum, spleen, 
lung and BM and compared their Sall1 expression levels to that of microglia using 
qPCR. We did not detect Sall1 expression in any other hematopoietic population 
apart from CNS resident microglia (Figure 10b). Additionally, we analyzed different 
lymphoid and non-lymphoid organs of Sall1GFP/+ mice by flow cytometry and failed 
to detect GFP expression in any hematopoietic (CD45+) cells outside of the CNS 




Figure 10 | Sall1 expression is restricted to the CNS within the hematopoietic system. (a) Flow cytometry 
analysis of GFP (Sall1) expression in CNS of Sall1GFP/+ and Sall1+/+ control mice. Cells were pre-gated on 
CD45+ cells. Shown are representative flow cytometry plots of at least 5 independent experiments (n > 5). (b) 
Quantitative RT-PCR of Sall1 mRNA expression (± SEM) of sorted cell populations derived from WT mice. 
Data were normalized to Pol2 expression. Alveolar MFs: CD45+Siglec-F+CD11c+, Lung CD11b+ DCs: 
CD45+Siglec-F-CD11c+MHCII+CD11b+, Lung CD103+ DCs: CD45+Siglec-F-CD11c+MHCII+CD103+, SP MF 
(spleen macrophages): F4/80hiCD11b+, SP NPs (neutrophils): Ly6G+SSChi, BM Monocytes (Mo): Lin-
CD11b+Ly6C+CD115+, microglia: CD45loLy6C-Ly6G-CD11b+F4/80+, Per. B cells (peritoneal B cells): B220+, 
peritoneal MFs: CD115+CD11b+F4/80+. (n = 2-3). (c) Flow cytometry analysis of GFP (Sall1) expression in 
different organs of Sall1GFP/+ and Sall1+/+ control mice. Cells were pre-gated on CD45+ cells (shown are 









































































































































































































































































































































































































































































































































































It has been described previously that Sall1 is expressed in kidney cells where it 
plays an essential role during organogenesis 86. Indeed, when we analyzed 
different whole tissue lysates of lymphoid and non-lymphoid organs from WT mice 
by qPCR, we found detectable levels of Sall1 not only in the brain and spinal cord, 
but also in kidney, liver and heart (Figure 11a). Similar results where obtained by 
flow cytometry in Sall1GFP/+ mice, where we detected Sall1 expression among non-
hematopoietic cells (CD45-) in the liver, kidney and to a small extent in heart tissue 
(Figure 11b,c). In the liver a small number of mainly epithelial cells (Epcam+) were 
found to be GFP+ (14% of CD45- cells) and in the heart, the negligible number of 
GFP+ cells (1%) correlated to endothelial cells (CD31+) (Figure 11b). We found 
12% GFP+ cells (among CD45- cells) in the adult kidney where Sall1 is expressed 
in the renal tubular epithelia and in stem cells as previously described 96,97.  
 
Figure 11 | Sall1 is expressed in a minor fraction of non-hematopoietic cells in kidney liver and heart. 
(a) Quantitative RT-PCR of Sall1 mRNA expression (± SEM) of total tissue lysates of different organs. (Pooled 
data of at least 2 individual experiments, n ≥ 4, LN n =3). Data were normalized to Pol2 expression. (b-c) 
Representative flow cytometry plots (b) and quantification of the frequency (±SEM) (c) of GFP (Sall1) 
expression in kidney, liver and heart of Sall1GFP/+ and Sall1+/+ control mice (gated on CD45- cells). (Pooled data 




















































































































































































































































It was previously shown that Sall1 is highly expressed by neuronal and glial 
progenitors in the CNS during embryogenesis, where it was implicated in cortical 
neurogenesis during CNS development 91. To examine more carefully whether 
other CNS-resident cells apart from microglia express Sall1 in the adult, we 
analyzed the CNS of Sall1GFP/+ mice by flow cytometry and immunohistochemistry 
(IHC). Unsupervised dimensionality reduction of the obtained flow cytometry data 
using the t-SNE algorithm overlaid with the GFP expression map showed that Sall1 
is mainly expressed by microglia and that GFP expressing CD45- cells were scarce 
(Figure 12a). This observation was verified by thorough analysis of different non-
hematopoietic populations, including astrocytes (GLAST+), oligodendrocytes 
(MOG+) and endothelial cells (CD31+), in conventional two-dimensional flow 
cytometry plots, showing that only CNS-resident microglia express GFP (Figure 
12b,c). Furthermore, within the adult CNS we did not detect notable GFP 
expression in CNS-resident cells apart from microglia (Iba-1+) by IHC of brain 
sections from Sall1GFP/+ mice. This includes neuronal precursors (radial-glia-like 
stem cells, GFAP+ or neuroblasts, DCX+), neurons (NeuN+, Calbindin+) or other 
non-neuronal cells such as astrocytes (GFAP+, S100B+) and oligodendrocytes 




Figure 12 | Sall1 expression is specific to resident microglia within the CNS. (a) Annotated t-SNE map 
depicts populations of total CNS cells of Sall1GFP/+ mice and color-coded overlay of Sall1 (GFP) expression. (b) 
Gating strategy of non-hematopoietic (CD45-) CNS-resident cells and representative flow cytometry plots for 
their GFP (Sall1) expression in Sall1GFP/+ mice. (c) Quantification (±SEM) of GFP+ cells by flow cytometry as 
shown in the gating strategy in b) in Sall1GFP/+ mice (n=3). (d) Immunohistochemistry (IHC) of cortical brain 
sections of Sall1GFP/+ mice for GFP (green), DAPI (blue) and either Iba-1 (microglia), NeuN (neurons), GFAP 
(astrocytes) or Olig2 (oligodendrocytes and their precursors) (red). Small images (without DAPI) display the 
magnification of the inset in the overview picture. (Scale bar: 20 µm in the overview image and 5 µm in the 
small images). (e) Quantification of d). Shown is the percentage of GFP+ cells (± SEM). Counted were 5-15 
sections of 3-5 mice. (f) Immunohistochemistry of CNS sections of Sall1GFP/+ mice for GFP (green), DAPI 
(blue), and in red GFAP (radial-glia-like stem cells), DCX (neuroblasts), Calbindin (Purkinje neurons), S100B 
(astrocytes) and MBP (oligodendrocytes), respectively. Small images (without DAPI) display the magnification 
of the inset in the overview picture. (Scale bar: 20 µm in the overview image and 5 µm in the small images). 



















































































































































































































































































In order to secure the immunologically unique status of the CNS, specialized 
macrophage populations can be found at the boarder areas. Based on a recent 
publication by Goldmann et al. some of these macrophages, namely meningeal 
and perivascular macrophages, are embryonically derived and long-lived whereas 
choroid plexus macrophages are slowly repopulated by circulating monocytes 52. 
To investigate whether these ‘CNS-associated’ macrophages are similar to 
microglia and also express Sall1 we quantitatively assayed their GFP expression in 
Sall1GFP/+ mice. As previously proposed 52, we identified CD206+ non-parenchymal 
macrophages but also CD206- macrophages / dendritic cells by flow cytometry. 
While macrophages residing in the choroid plexus were essentially negative for 
GFP, we found approximately 5% of other CNS-associated macrophages to be 
positive (Figure 13a-f). To further visualize GFP-expressing cells in the CNS of 
Sall1GFP/+ mice, we used unsupervised dimensionality reduction (t-SNE) of our 
single cell flow cytometry data, which also revealed that in the CNS, microglia are 
the prevailing population expressing Sall1 while GFP was detected only in a minor 
fraction of ‘non-microglial’ CNS cells (Figure 13b,c). In addition, we visualized 
these macrophages based on their location and commonly used macrophage 
markers in IHC, showing only little co-localization with GFP-labeled cells (Figure 
13e). Of note, this is a major advantage over the commonly used Cx3cr1GFP/+ 
reporter mouse which targets not only microglia but also the vast majority of ‘CNS-
associated’ myeloid cells (Figure 13f) 98. Taken together these data demonstrate, 
within the adult CNS and within the hematopoietic system, Sall1 expression is 





Figure 13 | Sall1 is not expressed by other CNS-associated myeloid cells. (a) Gating strategy of CNS-
resident myeloid cells and separately isolated choroid plexus (CP) cells. Representative Flow cytometry plots 
display frequencies of GFP+ cells in Sall1GFP/+ mice. MF: Macrophage. (b) Annotated t-SNE map and 
expression of markers in the identified populations of CD45+ CNS cells of Sall1GFP/+ mice. (c) as in b), t-SNE 
map depicts color-coded overlay of Sall1 (GFP), CD45 and CD206 expression of CD45+ cells of Sall1GFP/+ 
mice. (d) Quantification (±SEM) of GFP+ cells by flow cytometry as shown in the gating strategy in a) (n = 6). 
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(e) Immunohistochemistry of CNS sections of Sall1GFP/+ mice for GFP (green), DAPI (blue), Iba-1 or F4/80 
(microglia and CNS-MF, red) and CD31 (endothelial cells, gray), respectively. Small images without DAPI 
display the magnification of the inset in the overview picture. Representative pictures are shown. (n=2-4) 
(Scale bar: 20 µm in the overview image and 5 µm in the small images, arrowheads indicate Iba-1 and GFP or 
F4/80 and GFP double-positive microglia). (f) Frequency (±SEM) of GFP+ microglia and CD45hi MF of 
Sall1
GFP/+ and Cx3cr1GFP/+ reporter mice and of YFP+ and RFP+ microglia and CD45hi MF in tamoxifen treated 
Sall1
CreER
R26-yfp and Cx3cr1CreERR26-rfp mice, respectively. (Pooled data of at least 2 individual experiments, 
n=4-13). Cells were pregated on CD45+CD11b+F4/80+Ly6C-Ly6G-. 
6.2 The CNS environment alone does not imprint Sall1 expression  
Under physiological conditions, microglia are not replaced by circulating 
precursors. However upon experimental microglia depletion, the empty microglia 
niche is reconstituted rapidly. The origin of the newly formed microglia/microglia-
like cells is a matter of some debate. Recent reports suggest that the ontogeny of 
newly emerging microglia/microglia-like cells is dependent on the experimental 
setup and that they can be derived either from circulating precursors (BM-derived) 
in a BM transplantation setting or from an internal pool of CNS-resident cells 51,99-
101. Given that Sall1 represents a microglia signature gene, we addressed whether 
newly repopulated microglia/microglia-like cells also expressed Sall1. As a model 
for CNS-internal repopulation of microglia upon depletion, we treated Sall1GFP/+ and 
WT mice with Csf-1R inhibitors (PLX5622) for 2 weeks. As recently described by 
Elmore et al., this treatment leads to a rapid depletion of microglia, which are fully 
repopulated by the remaining CNS-resident microglia within one week after 
treatment (Figure 14a) 101. We found the few remaining microglia of Sall1GFP/+ mice 
to be GFP+ 1 day after PLX5622-treatment (Figure 14b-d). Two weeks after 
discontinuing PLX5622-treatment, newly formed ‘microglia’ expressed Sall1 
similarly to the untreated control mice (Figure 14b-d). On the other hand, when we 
used congenic Sall1GFP/+ BM chimeras (Sall1GFP/+(CD45.1)àWT(CD45.2)), we 
found that after exposure to Csf-1R inhibitors, newly repopulated microglia-like 
cells were BM-derived (CD45.1) and did not express Sall1 even 4 weeks after 
repopulation (Figure 14e,f). Also in the recently described Cx3cr1CreERiDTR model 
combined with BM chimerism 100, we could show that the newly BM-derived 





Taken together, new microglia-like cells originated from BM-derived cells after 
microglial depletion do not initiate Sall1 transcription, whereas new microglia 
derived from a CNS-resident pool retain Sall1 expression. Previous reports also 
suggested that BM-derived microglia-like cells have an altered genetic signature 
compared to yolk sac or internally-derived microglia upon depletion, whereas the 
genetic profile of the latter two remained largely identical including the expression 
of Sall1 100. Our data indicate that Sall1 is a marker for bona fide microglia and can 
be used to discriminate the ontogenically different embryonically-derived microglia 






Figure 14 | BM-derived ‘microglia-like’ cells do not express Sall1. (a-d) Sall1GFP/+ mice and Sall1+/+ 
littermates were treated with PLX5622 food for 2 weeks. Bar graphs (a) show microglia numbers at d0, d6 and 
d14 after treatment stop or in untreated mice. Scatter plots (b) and representative IHC images (c) and flow 
cytometry plots (d) (pre-gated on CD45+ cells) show the frequency (± SEM) of GFP+ microglia at d0, d6 and 
d14 after treatment stop or in untreated mice. (Pooled data of 2 independent experiments, n = 3-4). (Scale bar: 
100 µm). (e-f) Representative flow cytometry plots (e) and scatter graphs (f) show frequency (± SEM) of GFP+ 
microglia (pre-gated on CD11b+F4/80+Ly6C-Ly6G- cells) in congenic Sall1GFP/+(CD45.1)àWT (CD45.2) BM 
chimeras at d6, d14 and d28 after PLX5622 treatment (2 weeks) and untreated Sall1GFP/+ (CD45.1) controls. 
(Pooled data of 2 independent experiments, n = 2-3 for Sall1GFP/+à WT BM chimeric mice and n = 4 for 
Sall1
GFP/+ control mice). (g-h) Representative flow cytometry plots (g) and scatter plots (h) display the 
frequency (± SEM) of GFP+ microglia of tamoxifen/DTx-treated Sall1+/+ (CD45.1)àCx3cr1CreERiDTR (CD45.2) 
or Sall1GFP/+ (CD45.1)à Cx3cr1CreER iDTR (CD45.2) BM chimeras (pre-gated on CD11b+F4/80+CD45.1loLy6C-
Ly6G- cells) on d0, d11 and d21 after treatment. Untreated Sall1GFP/+ mice served as a GFP control. (Pooled 
data of 2 individual experiments, n = 4 for d11 and d21, n = 1 for d0 and untreated Sall1GFP/+). One-way Anova, 





































































































































































































































































































































































































































































Similarly in the context of neuroinflammation, it has been reported that microglia 
become activated, yet maintain a signature distinct from invading myeloid cells 50. 
Thus, we investigated whether CNS-infiltrating myeloid cells would also acquire 
Sall1 expression after recruitment to the brain. The neuroinflammatory model of 
experimental autoimmune encephalomyelitis (EAE), a preclinical model for multiple 
sclerosis, is characterized by massive infiltration of monocytes and their 
subsequent differentiation into monocyte-derived cells such as monocyte-derived 
DCs or inflammatory macrophages 102,103. In order to distinguish infiltrating immune 
cells from resident irradiation-resistant microglia, we generated congenic (CD45.1 
or CD45.2) Sall1GFP/+ BM chimeras (Sall1GFP/+àWT and WTàSall1GFP/+) and 
immunized them s.c. with MOG35-55/CFA. At peak disease, microglia continued to 
express Sall1, while CNS-invading myeloid cells including neutrophils and 
monocyte-derived cells did not (Figure 15a,b). Similar results were observed using 
Sall1GFP/+ mice without BM chimerism (Figure 15c). As in parts shown previously 
84, this demonstrates that Sall1 expression is inherent to resident microglia and that 
the CNS tissue environment does not induce Sall1 expression on myeloid 
populations under inflammatory conditions. 
 
 

























































































































































(a-b) CNS of Sall1GFP/+(CD45.1)à WT(CD45.2) or WT(CD45.2)àSall1GFP/+(CD45.1) BM chimeras were 
analyzed for GFP expression at peak disease of MOG35-55/CFA induced EAE. (a) Gating strategy is shown as 
an example of a Sall1GFP/+(CD45.1)àWT(CD45.2) BM chimeric mouse. (b) Histogram depicts the percentage 
of GFP expression of MCs and neutrophils (of Sall1GFP/+(CD45.1)àWT(CD45.2) BM chimeras) and microglia 
(of WT(CD45.1)àSall1GFP/+(CD45.2) BM chimeras) as gated in a) and graph shows the quantification (± SEM). 
(Pooled data of two individual experiments, n = 6-8). (c) Representative histograms and quantification (±SEM) 
of GFP (Sall1) expression in MCs (gated on CD45hiCD11b+CD11c+MHCII+Ly6C+), neutrophils (gated on 
CD45hiCD11b+Ly6G+), CD4+ T cells (gated on CD45hiCD11b-CD4+) and microglia (gated on CD45loLy6C-Ly6G-
CD11b+) in Sall1GFP/+ mice at peak disease of MOG35-55/CFA induced EAE. (Pooled data of 3 individual 




6.3 Csf1r and Tgfbr2 have different contributions to microglia homeostasis 
To determine the utility of the Sall1 promoter for conditional gene targeting in 
microglia, we used Sall1CreER mice, which express the tamoxifen-inducible Cre-
recombinase under the Sall1 promoter 104. We found the Sall1CreER strain to 
efficiently recombine in microglia (>90%) when crossed to the reporter/fate-map 
strain (R26-yfp), whereas no other hematopoietic cells or other CNS-resident cells 
were labeled (Figure 13f, Figure 16a and data not shown).  
Csf-1R signaling is critical for the embryonic development of microglia 46. As 
described above and suggested previously, in the adult, Csf-1R signaling blockade 
by Csf-1R kinase inhibitors led to the depletion of microglia 101. However Csf-1R 
inhibitor treatment is not only specific for Csf-1R but also blocks other tyrosine 
kinases such as FLT3, PDGFR and KIT 51. We could show that upon tamoxifen 
treatment (Figure 16a), adult microglia were rapidly depleted in Sall1CreERCsf1rfl/fl 
mice, with varying efficiencies between 70-90% in different brain regions (Figure 
16c-g). As described in other microglia depletion models 51, also in this model they 
were repopulated within 7 days (Figure 16d,e). To analyze whether the 
untargeted, remaining microglia could replenish the empty microglia niche, we 
examined their proliferation by IHC and flow cytometry and found that more than 
half of the remaining microglia were Ki67+ and thus highly proliferative (Figure 
16g,h). Therefore, in addition to being critical for their development 46, this specific, 
inducible approach demonstrates that Csf-1R signaling in microglia is crucial for 





Figure 16 | Csf-1R signaling is crucial for microglia maintenance. (a) Flow cytometry plots display the 
frequency of YFP+ microglia (pre-gated on CD45loLy6G-Ly6C-CD11b+) of Sall1CreERR26-yfp mice and R26-yfp 
control littermates on d3 after tamoxifen treatment. (Representative plots of at least 5 similar individual 
experiments, n = 10). (b) Scheme of the experimental setup for c-h. Sall1CreERCsf1rfl/fl mice and Csf1rfl/fl 
littermates were treated with tamoxifen (2.5 mg i.p.) for 5 consecutive days and analyzed at different time 
points after treatment. (c-d) Representative flow cytometry plots (c) show the percentage of microglia (Siglec-
H+) (pre-gated on CD45+CD11b+ cells) and graph (d) displays the total cell number (± SEM). (Pooled data of 2 
independent experiments, n = 4-7). (e) IHC of cortical brain sections of tamoxifen treated Sall1CreERCsf1rfl/fl and 
Csf1r
fl/fl mice for Iba-1 (green, microglia) and DAPI (blue) at d0, d7 and d14 after tamoxifen treatment. (Scale 
bar: 20 µm). (f) Graph (± SEM) shows microglia counts in different brain areas at d0 after tamoxifen treatment. 
(n = 3-5 sections of 2 mice). (g) Representative IHC images for Iba-1 (green), DAPI (blue) and Ki67 (yellow) in 
the thalamus at d0 after tamoxifen treatment. (Scale bar: 20 µm). (h) Representative flow cytometry plots (pre-
gated on CD45loCD11b+ microglia) and graph (± SEM) depict the percentage of Ki67+ microglia at d0 after 
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*** * *** ** ***
Results 
61 
A recent report suggested a TGF-β-dependent gene signature in microglia and 
claimed that TGF-β is critical for the development and maintenance of microglia 50. 
Utilizing Sall1CreER mice, we wanted to confirm the importance of TGF-βR signaling 
in adult microglia. To do so, we crossed the Sall1CreER mice to the Tgfbr2fl/fl mice 
and exposed adult mice to tamoxifen to delete TGF-βR on microglia (Figure 17a). 
Recombination frequency and deletion of Tgfbr2 was verified by qPCR (Figure 
17b). The deletion of Tgfbr2 in microglia of tamoxifen treated Sall1CreERTgfbr2fl/fl 
mice led to a moderate increase in microglial cell numbers on d6 after treatment, 
(Figure 17c). Three days after tamoxifen treatment, microglia lacking TGF-βR 
exhibited altered cell morphology including shorter, thicker dendrites and enhanced 
Iba-1 immunoreactivity characteristically seen in reactive microglia (Figure 17d). 
Furthermore we observed an increased number of proliferating (Ki67+) microglia, 
which could explain the elevated microglia numbers (Figure 17d). Also by flow 
cytometry, we could show that TGF-βR-deficient microglia present an altered 
surface phenotype by up-regulation of CD45, F4/80, MHCII and intermediate levels 
of CD11c and Siglec-1 (Figure 17e,f) 105. Of note, the marker Siglec-H, which was 
shown to be expressed by microglia but not by other tissue macrophages 32, was 
down-regulated upon deletion of TGF-βR on microglia.  
To exclude the possibility that the CD45int-hiF4/80hi population, which we observed 
after deletion of microglial Tgfbr2, was derived from circulating monocytes, we 
crossed the Sall1CreERTgfbr2fl/fl mice to the reporter/fate-map strain R26-yfp 
(Sall1CreERTgfbr2fl/flR26-yfp). Upon tamoxifen treatment, YFP+ cells in 
Sall1CreERTgfbr2fl/flR26-yfp mice completely overlapped the CD45int-hiF4/80hi 
population, whereas other myeloid cells in the CNS or blood were negative for YFP 
(Figure 17g,h and data not shown). This demonstrates that CD45int-hiF4/80hi cells 
were indeed bona fide microglia, which have up-regulated CD45. In addition, 
Tgfbr2-deficient microglia displayed elevated expression levels of Il1, Tnfa and 
Cxcl10 similar to microglia isolated from LPS-challenged mice, which we used as a 
positive control for reactive microglia (Figure 17i). Taken together these results 
show that TGF-β signaling in microglia is not crucial for their survival but is 





Figure 17 | TGF-βR signaling maintains ‘resting’ microglia phenotype. (a) Scheme of the experimental 
setup for a-i). Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice or Sall1CreERR26-yfp and Sall1CreERTgfbr2fl/fR26-yfp mice 
were treated with tamoxifen (2.5 mg i.p.) on three consecutive days and were analyzed at d0, d3 or d6 after 
treatment. (b) Quantitative qPCR of Tgfbr2 mRNA expression of microglia sorted from Sall1CreERTgfbr2fl/fl and 
Tgfbr2
fl/fl mice on d0 after tamoxifen treatment. Data were normalized to Pol2 expression (pooled sample of 3 - 
4 mice). (c) Quantification (± SEM) of microglia numbers (assessed by flow cytometry analysis gated as in 
upper row of e) on d0, d3 and d6 after tamoxifen treatment. Numbers are displayed as ratios to control 


































































































































































































































































































































































































































(d) Representative IHC images of CNS sections of Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice on d3 after 
discontinuing treatment for Iba-1 (green), Ki67 (red) and DAPI (blue). Arrowheads indicate Iba-1 and Ki67 
double-positive cells. (Scale bar: 50 µm, n = 1 - 2). (e) Representative flow cytometry plots show frequency of 
microglia (pre-gated on CD45+Ly6C-Ly6G- cells) and expression of Siglec-H vs. CD11c on d6 after tamoxifen 
treatment. (2 individual experiments, n = 5-6). (f) Histograms display the expression of different surface 
markers vs. FMO on microglia (gated as in upper row of e) of Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice at d6 after 





R26-yfp mice and control Sall1CreERR26-yfp and Sall1CreERTgfbr2fl/f mice on d6 after tamoxifen 
treatment. (g) Representative flow cytometry plots show YFP+ cells (pre-gated on CD45+ cells). (h) Scatter 
plots show frequency (± SEM) of YFP+ microglia (CD45+Ly6C-Ly6G-F4/80+) and monocytes 
(CD45+Ly6ChiCD11b+Ly6G-). (Pooled data of 2 individual experiments, n = 3 - 5). (i) Quantitative qPCR 
analysis of Il1, Tnfa and Cxcl10 mRNA expression (± SEM) of microglia (CD45lo/intGr1-F4/80+) sorted from LPS 
treated or untreated WT mice, and of tamoxifen treated Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice on d0 and d6 
after tamoxifen treatment. Data were normalized to Pol2 expression. (n = 2 replicates, 3 - 4 mice were pooled 
for each sample). 
6.4 Role of Sall1 and Tgfbr2 during microglia development 
As discussed in the introduction, microglia derive from primitive yolk sac 
progenitors that invade the developing CNS around E9 46. To assess whether 
these early progenitors already express Sall1 we set up timed matings of Sall1GFP/+ 
reporter mice and analyzed the CNS of the offspring at different embryonic and 
postnatal time points. We did not observe expression of Sall1 in yolk sac 
precursors or early embryonic microglia in the CNS at E11.5 (Figure 18a,b). We 
observed a the down-regulation of CD45 and F4/80 as well as the up-regulation of 
CD11b in microglia as they mature (Figure 18c). Sall1 is expressed in the majority 
of these cells starting at E14.5 (Figure 18a-c), when microglia also obtain their 
typical ramified morphology 45 Sall1 expression further increases so that all mature 
microglia (CD45loF4/80loCD11bhi) express Sall1 while immature precursors 
(CD45hiF4/80hiCD11blo) do not express this signature gene (Figure 18a,b). Of 
note, CD11c expression is inversely regulated to CD11b and down-regulated with 
the maturation of microglia (data not shown). We set up timed matings of Sall1GFP/+ 
mice, to analyze homozygous Sall1GFP/GFP mice just before birth at E18.5. Due to 
the knock-in of GFP into the endogenous Sall1 locus, these mice have no 
functional Sall1 expression and would die within the first 24h after birth 86. 
Interestingly, despite the early expression of Sall1 in microglia it does not seem to 
be essential for their development, as we did not observe differences in microglia 
numbers between homozygous Sall1GFP/GFP mice and control Sall1GFP/+ or Sall1+/+ 
mice (Figure 18d). Similar results have also recently been described for Sall1-
deficient microglia in the retina, which develop in normal numbers but show a more 
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activated morphology 84. Further studies will be required to delineate the impact of 
Sall1 deficiency in microglia on their morphology, tissue distribution and function as 
well as the related effects on CNS development.  
Based on our findings that TGF-βR signaling in microglia is not crucial for their 
survival but is essential to keep them in a non-reactive state, we wanted to assess 
the importance of TGF-βR signaling during microglia development. To address 
this, we set up timed matings of Cx3cr1CreERTgfbr2fl/fl as well as Sall1CreERTgfbr2fl/fl 
mice and treated the pregnant mothers with Tamoxifen (5mg o.g.) at E9.5 or E14.5 
respectively. Using this approach we were able to delete Tgfbr2 in early CX3CR1
+ 
yolk sac precursors and microglia 46 or only in Sall1+ microglia. In contrast to recent 
reports 50, we did not detect a decrease in overall microglia numbers between cre+ 
animals and controls in either model. However we observed an arrest of microglial 
development in an immature state indicated by inversed ratios of F4/80hi to F4/80lo 
cells (Figure 18e,f). This change was more pronounced in Sall1CreERTgfbr2fl/fl mice. 
Given the limited data on this topic so far, we cannot rule out a contribution of fetal 
liver derived monocytes to the population of F4/80hi cells observed in conditional 
TGF-βR deleted mice. 
Taken together these results show that Sall1 is expressed early during 
development in CNS-resident microglia but is not essential for their survival. 
Likewise, TGF-βR signaling is not essential for the survival of developing microglia 
however it is required for a proper maturation/differentiation of these cells. Further 
studies need to be performed to assess the different aspects of microglia 





Figure 18 | Expression of Sall1 and Tgfbr2 during microglia development. (a) Representative flow 
cytometry plots show frequency of GFP+ microglia (F4/80hi and F4/80lo, pregated on CD45+Ly6C-Ly6G-) in the 
yolk sac (YS) and CNS of Sall1GFP/+ mice at embryonic days E11.5 and E17.5 and at postnatal day P6. (Pooled 
data of 2 independent experiments, n = 3-10. (b-c) Scatter plots show frequencies (± SEM) of GFP+ microglia 
(b) and of F4/80hi and F4/80lo populations (c) during different developmental time points in YS and CNS of 
Sall1
GFP/+ mice. (Pooled data of 2 independent experiments, n = 7-19). (d) Representative flow cytometry plots 








































































































































































































































































































































































































































































































































































































































+/+, Sall1GFP/+ and Sall1GFP/GFP mice at embryonic day E18.5. (Pooled data of 3 independent experiments, 
n = 7-16). (e-f) Representative flow cytometry plots and scatter plots show frequencies and numbers (± SEM) 
of microglia (pregated on CD45+Ly6C-Ly6G-) at embryonic day E18.5 in Cx3cr1CreERTgfbr2fl/fl and Tgfbr2fl/fl 
mice treated with a single dose of Tamoxifen (5mg o.g.) at E 9.5 (e) or in Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice 
treated similarly at E14.5 (f). (Pooled data of 2 independent experiments, n = 9-19). 
6.5 Sall1 controls the transcriptional signature of microglia 
Given the high expression of Sall1 in microglia, we sought to identify its function in 
vivo. The Sall1CreER allele has been targeted into the Sall1 locus, therefore 
Sall1CreER/fl mice (heterozygous for both alleles) allow inducible ablation of Sall1 
expression in microglia after tamoxifen treatment. We performed RNA-sequencing 
(RNA-seq) to examine gene expression profiles of microglia sorted from tamoxifen 
treated adult Sall1CreER/fl mice and Sall1fl/fl control littermates (Figure 19a,b). 
Microglia were obtained with > 98% purity and we did not observe differences in 
the numbers of microglia between Sall1CreER/fl and Sall1fl/fl mice (Figure 19b, data 
not shown). The absence of Sall1 was confirmed in Sall1CreER/fl microglia (Figure 
19c). Hierarchical clustering of the differentially expressed genes showed a clear 
segregation between control and Sall1-deficient microglia (Figure 19d). 
Transcriptional changes assessed by RNA-seq revealed that from a total of 12,673 
expressed genes, 847 genes were significantly up-regulated and 608 genes were 
down-regulated in microglia lacking Sall1 (Figure 19e,f). Among the fifty most 
significantly altered expression features, genes associated with inflammation and 




In the past few years it has become clear that not only the ontogeny varies 
between different macrophage populations but also their gene expression 
signatures, which can be imprinted by the local tissue microenvironment 30,31. By 
comparing differentially regulated genes of control microglia vs. Sall1-deficient 
microglia, we found that many of the previously described microglia signature 
genes (as shown in 32,106) such as P2ry12, Serpinf1, or Slc2a5, were down-
regulated upon Sall1-deletion (Figure 19h). In addition, genes associated with the 
identity of other tissue macrophages were induced in microglia upon deletion of 
Sall1 32. Among those were Msr1 and Stard13, usually specifically expressed in 
peritoneal macrophages, Cyp4f18, Itgal and Cd69, typically high in alveolar 
macrophages and Spic, Vcam1, Igf1 and Ahr normally found at high levels in 
splenic red pulp macrophages (Figure 19h). 
Similar changes in gene expression profiles were found in Sall1-deficient microglia 
isolated from tamoxifen-treated Cx3cr1CreERSall1fl/fl mice. In these mice, deletion of 
Sall1 is targeted to CX3CR1
+ myeloid cells including microglia and CNS-associated 
macrophages but not to any other CNS-resident cells as previously shown (Figure 
19d, Figure 13f) 19,107. This experiment clearly demonstrates that Sall1 acts in a 
microglia-intrinsic manner and is not the result of collateral Sall1 loss outside the 
microglia compartment. Overall these data demonstrate a pronounced change in 




Figure 19 | Gene expression profile of Sall1-deficient microglia. (a) Scheme of the experimental setup. 
Sall1
CreER/fl and Sall1fl/fl mice were treated 5 times with tamoxifen (2.5 mg i.p.) every 2nd day and microglia were 
sorted one day after the last treatment. (b) Gating strategy and cell numbers (± SEM) of sorted microglia used 
for NGS. (n = 4). (c-h) Gene expression data obtained from NGS (3 replicates of Sall1CreER/fl and Sall1fl/fl mice, 
one sample of Cx3cr1CreERSall1fl/fl mice , 3-5 mice pooled per sample). (c) Normalized expression count (± 
SEM) of Sall1 expression in microglia. Unpaired t-test, ***p < 0.001. (d) Heat map and cluster analysis of 
differentially expressed genes. 471 genes were significantly altered to a minimum significance threshold of p < 
0.001. (e) Volcano plot showing log2
 ratios vs. p values (log10) of all 12,673 detected genes. Genes with 
highest significance values are annotated. (f) Venn diagram of differentially expressed genes. (g) Bar graph 
displays the fold change of the 50 most significantly altered genes of microglia derived from tamoxifen-treated 
Sall1
CreER/fl compared to Sall1fl/fl mice. (h) Heat maps display log2 ratios of macrophage signature genes 











































































































































































































































































































































































































































































































































































6.6 Sall1 regulates the microglia phenotype and function during tissue 
homeostasis and disease 
Pathway analysis performed by MetaCoreTM demonstrated that genes involved in 
immune system (IS) responses including cytokines/chemokines, cell cycle, 
phagocytosis and neurogenesis were most differently regulated in microglia lacking 
Sall1 (Figure 20a). For example, the pro-inflammatory oxidase Nox2 (Cybb), which 
is implicated in microglia-mediated neurotoxicity 106,108, was highly expressed by 
Sall1-deficient microglia but only at low levels in control microglia. The expression 
of interferon response and regulatory genes such as Ifit3, Ifit2, Ifitm3, Mx1 and Irf7, 
which are usually expressed under inflammatory conditions, were greatly 
enhanced in Sall1-deficient microglia 109,110. The aryl hydrocarbon receptor (Ahr), 
usually not present on microglia isolated from healthy brain, was expressed in 
microglia lacking Sall1. Ahr is a transcriptional regulator critical for innate immunity 
by promoting macrophage survival and ROS production among other functions 
111,112. Axl is part of a phagocytic receptor and expressed at low levels in the 
healthy CNS but it is up-regulated in microglia in inflammation 113. Microglia lacking 
Sall1 also show significantly elevated expression levels of Axl. Along those lines, 
we assessed the phagocytic capacity of ex vivo isolated microglia from Sall1CreER/fl 
mice in comparison to controls using pH-sensitive pHrodo bioparticles. Comparing 
the frequency of pHrodo+ particles in microglia after 4 h of culture we observed a 
significant increase in phagocytic activity in Sall1-deficient microglia (Figure 
20b,c).  
Additionally, we wanted to address whether Sall1 deletion in microglia would 
impact the outcome of neuro-inflammatory disorders. To assess this we immunized 
Sall1CreER/fl and Sall1fl/fl mice s.c. with MOG35-55/CFA as described before to induce 
EAE. Monitoring the animals until peak disease, we did not observe vast 
differences in the clinical scores (Figure 20d). Similarly, the day of disease onset 
and the maximal clinical score did not vary between experimental and control 
group (Figure 20e). When we analyzed the CNS of immunized animals at peak 
disease, we observed a significant increase in infiltrating MCs while the number of 
other myeloid cells present at that time point remained similar (Figure 20f,g). This 
indicates that the cellular composition in the CNS during neuro-inflammation is 
altered upon Sall1 deletion in microglia. The effects of this compositional change 
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on the clinical outcome and the recovery phase remain to be monitored in more 
detail. Altogether these data propose that Sall1 is required for microglia to maintain 
their physiological expression phenotype to fulfill their homeostatic functions in the 
CNS and protect the sensitive surrounding tissue. Further studies will be necessary 
to characterize the impact of the loss of Sall1 in microglia in more detail. 
 
 
Figure 20 | Sall1-deficient microglia show altered functional properties. (a) Gene expression analysis of 
microglia derived from tamoxifen treated Sall1CreER/fl and Sall1fl/fl mice as described in Figure 19. Heat maps 
display log2 ratios of Sall1-regulated genes clustered to their indicated GO-pathways. IS: Immune system. (b-
c) Analysis of phagocytic activity of microglia ex-vivo isolated from tamoxifen treated Sall1CreER/fl and Sall1fl/fl 
mice. (b) Representative IHC for Iba-1 (green) and pHrodo (red) display phagocytically active microglia.  
d
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(c) Representative flow cytometry plots and scatter plots show frequencies (± SEM) of pHrodo+ microglia 
(pregated on CD45+CD11b+Gr1-). (Pooled data of 3 independent experiments, n = 10-14). (d-g) Tamoxifen 
treated Sall1CreER/fl and Sall1fl/fl mice were analyzed at peak disease of MOG35-55/CFA induced EAE. (n = 6-11) 
(d) Graph displays clinical score (± SEM) over days post injection (dpi). (e) Scatter plots show maximal clinical 
score and day of onset of clinical EAE disease symptoms (± SEM). (f) Representative flow cytometry plots 
show frequencies of microglia, monocytes and MCs (pregated on CD45+CD11b+Ly6G-). (g) Bar graphs display 
frequencies (± SEM) of neutrophils (gated on CD45+CD11b+Ly6C+) and microglia, monocytes and MCs (gated 
as shown in f) in the CNS. 
 
In line with the RNA-seq data showing that Sall1 maintains the transcriptional 
signature specific to microglia, we also observed significant morphological 
alterations, like shorter, thicker processes and bigger cell soma, by using 3D 
reconstruction of individual microglia cells (Figure 21a, b). The morphological 
change coincided with an increase in microglial cell numbers in the hippocampus 
(Figure 21c).  
Among others adult hippocampal neurogenesis occurs in the subgranular zone 
(SGZ) of the dentate gyrus, where GFAP-expressing radial-glia-like stem cells give 
rise to doublecortin (DCX)+ neuroblasts, which then differentiate into new granule 
cell neurons 114. Multiple factors including pathological conditions can influence 
adult neurogenesis as reflected by altered proliferation, differentiation and survival 
of precursor cells. We found the number of GFAP-expressing radial-glia-like stem 
cells and the number of proliferating (DCX+Ki67+) neuroblasts unchanged in the 
dentate gyrus of tamoxifen treated Sall1CreER/fl mice compared to control mice. 
However differentiating (DCX+Ki67-) neuroblasts were significantly decreased in 
Sall1CreER/fl mice (Figure 21d-f). Similar results were obtained in tamoxifen treated 
Cx3cr1CreERSall1fl/fl mice (Figure 21g) again demonstrating that the phenotype is 
driven by microglia-intrinsic processes.  
Of note, the few Sall1 expressing CD45- cells in the adult liver and kidney (Figure 
11c) are also targeted using Sall1CreER/fl mice. After tamoxifen treatment, Sall1 
deletion in these cells did not result in overt tissue inflammation as assayed by 
multiplex immunoassay in the serum, spleen, liver and kidney. IL-1, IL-6, TNF-α 
and IL-10 were detected at low levels but no major differences were found between 
tamoxifen treated Sall1CreER/fl and Sall1fl/fl animals (Figure 21h). GM-Csf, IFN-γ, IL-
2 and IL-12 were below detection limit (data not shown). In addition, after long-term 
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tamoxifen treatment, Sall1CreER/fl mice remained viable and healthy and no apparent 
clinical phenotype was observed (data not shown). 
If the cell-intrinsic loss of Sall1 leads to microglia activation, we questioned whether 
extrinsic activation triggers would in turn regulate Sall1. We injected WT mice with 
LPS i.p. and sorted microglia 24 h later. Microglia isolated from LPS-challenged 
mice down-regulated Sall1 compared to untreated control mice (Figure 21i). As 
demonstrated earlier, loss of TGF-βR signaling likewise results in aberrant reactive 
microglia, which interestingly also showed reduced levels of Sall1 (Figure 21i). 
Taken together, these data support that under physiological conditions, the 
function of Sall1 is to repress ‘activatory’ genes in microglia and conversely, Sall1 
down-regulation / deletion allows microglia activation. In turn this demonstrates, 
that Sall1-deficiency in microglia results in disturbed CNS homeostasis as 




Figure 21 | Sall1 deletion in microglia leads to changes in adult neurogenesis. (a-f) Sall1CreER/fl and 
Sall1
fl/fl mice were treated with tamoxifen food for at least 5 weeks. (a) 3D reconstruction of Iba-1+ (green) 
microglia in tamoxifen-treated Sall1CreER/fl and Sall1fl/fl mice. Representative images in cortex and 
hippocampus. (Scale bar: 10 µm). (b) Quantification (± SEM) of the ratio of the microglial cell body diameter at 
its widest expansion including its processes over the cell soma diameter. (n = 10-21 microglial cells in 
hippocampus, cortex, cerebellum. Pooled data of 3 mice). (c) Graph shows cell counts of Iba-1+ cells in 
hippocampal CNS sections of tamoxifen treated Sall1CreER/fl mice and Sall1fl/fl littermates. (2-3 sections 

















































































































































































































































































































































(d-e) IHC of CNS sections (hippocampus) of tamoxifen treated Sall1CreER/fl mice and Sall1fl/fl littermates for 
DAPI (blue), GFAP (red, astrocytes and neuronal progenitor cells) (d) or DAPI (blue), doublecortin (DCX, 
green, neuroblasts) and Ki67 (red, proliferating cells) (e). Arrowheads in e) indicate proliferating neuroblasts. 
Small images display the magnification of the inset in the overview picture. (Scale bar: 50 µm, inset: 20 µm). (f) 
Graphs (± SEM) display GFAP staining intensities in the granule cell layer (indicated by the dotted line in d) as 
well as cell counts of proliferating (DCX+Ki67+) and differentiating (DCX+Ki67-) neuroblasts (as in e). (n = 4-10 
mice). (g) Graph (± SEM) displays cell counts of DCX+ neuroblasts in hippocampal brain sections of tamoxifen 
treated Cx3cr1CreERSall1fl/fl and Cre- control littermates (n = 3-4). (h) Graphs (±SEM) display levels of IL-1, IL-6, 
TNF-α and IL-10 (pg/mg) in serum and whole tissue lysates of spleen, kidney and liver of untreated control 
mice and tamoxifen treated Sall1CreER/fl and Sall1fl/fl mice at d6 after treatment start assessed by multiplex 
immunoassay. (n = 3 for Sall1CreER/fl and Sall1fl/fl mice, n = 2 for untreated control mice). (i) Quantitative qPCR 
analysis of Sall1 mRNA expression of microglia (CD45lo-intGr1-CD11b+) sorted from LPS treated or untreated 
WT mice, and of tamoxifen treated Sall1CreERTgfbr2fl/fl and Tgfbr2fl/fl mice on d6 after tamoxifen treatment (as in 
Fig. 3d). Data were normalized to Pol2 expression. (n = 2, 3-4 mice were pooled for each sample). Unpaired t-





7.1 Identification of Sall1 as a transcription factor specific to microglia  
Over the past decade, it has become clear that most tissue macrophages have 
embryonic origins, and are self-maintained throughout adulthood in the absence of 
inflammatory incidents, rather than being constantly replenished by circulating 
monocytes 115. Initially, macrophages were considered to perform primarily 
immune-related functions. But a new picture is emerging, in which control and 
regulation of tissue homeostasis are carried out by local macrophage populations. 
Advances in cell fate mapping and deep transcriptional profiling illustrate a highly 
specialized expression signature within tissue macrophages, depending on the 
tissue environment in which they reside 30-32. Despite the intensive research our 
understanding of microglia biology is still rather limited due to technical limitations 
and adverse targeting effects of previous models. The generation of the 
Cx3cr1CreER strains, in which successful targeting in microglia can be achieved, 
have advanced the microglia field significantly 19,59. However other myeloid cells 
expressing the fractalkine receptor (CX3CR1) including kidney and intestinal 
macrophages are also targeted. Furthermore, Cx3cr1 is highly expressed by CNS-
associated MF in the meninges, choroid plexus and perivascular space generating 
an important drawback of this model with regards to dissecting the individual 
contributions of CNS-resident microglia and CNS-associated MF in settings of CNS 
homeostasis and inflammation. Here we identified the transcriptional regulator 
Sall1 as virtually exclusive to microglia within the MPS and wider hematopoietic 
system as well as within the adult CNS. Interestingly, Langerhans cells, which are 
partly derived from yolk sac macrophages as well 116, do not express Sall1. 
Similarly in the testes, which are also considered partially immune privileged like 
the CNS, macrophages are negative for Sall1. In addition, Sall1 expression was 
not detected in BM-derived microglia-like cells repopulating the empty microglia 
niche after depletion in a chimeric setting. This suggests that microglia identity and 
their characteristic expression of Sall1 are made up of a combination of ontogeny 
and imprinting by the local tissue environment. The specificity of Sall1 to bona fide 
microglia finally allows for microglia specific targeting in vivo via the Sall1 locus. 
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7.2 Targeting microglia in vivo using the Sall1 locus 
Using knockout mice it has been well established that Csf-1R signaling is crucial 
for the development of microglia 46. Based on these finding and the data obtained 
from treatment with Csf-1R inhibitors it has also been claimed that Csf-1R signaling 
is essential for microglia survival and homeostasis under steady state conditions 
46,101. However this has never been conclusively demonstrated due to drawbacks in 
the respective models like impaired survival of Csf-1R knockout mice 28 or targeting 
of other receptor tyrosine kinases like FLT3 or KIT by the use of Csf-1R inhibitors 
from Plexxikon 51. Utilizing the tamoxifen-inducible Sall1CreER mouse strain, here we 
were able to show for the first time that Csf-1R signaling is indeed critical for the 
homeostasis and maintenance of adult microglia. By treating adult 
Sall1CreERCsf1rfl/fl mice with tamoxifen, we observed a pronounced reduction of 
microglia numbers in all brain areas compared to littermate controls. As described 
previously 101, the empty microglia niche is repopulated within 7 days by the CNS-
intrinsic proliferation of microglia that in all likelihood escaped targeting. 
In addition to Csf-1R, TGF-β signaling has been claimed to be crucial for microglia 
development and possibly also homeostasis 50. By specifically deleting TGF-βR 
from microglia under steady state conditions we show that loss of TGF-βR 
signaling results in the rapid transformation of surveying microglia towards reactive 
phagocytes while microglia numbers remain largely unchanged. The slight 
increase in microglia numbers observed at day 6 after tamoxifen treatment can be 
attributed to the increased proliferation of the activated TGF-βR-deficient microglia. 
Furthermore when we deleted TGF-βR from microglia during embryonic 
development, we observed alterations in the maturation status of microglia, while 
the total cell number again remained unchanged. This suggests that TGF-βR 
signaling is not critical for microglia survival but allows for proper maturation and a 
homeostatic activation profile. Further studies will be needed to dissect and define 
the role of TGF-βR in microglia in greater detail. Along those lines, there might be a 
link between TGF-βR signaling and Sall1 expression and/or function in microglia. 
For wing morphogenesis in Drosophila, it has been shown that expression of spalt 
and spalt-related gene are activated in response to the TGF-β homologue 
decapentaplegic (dpp) 117. Our data show that similar to activated microglia of LPS 
treated mice, Sall1 expression is strongly reduced in microglia lacking TGF-βR. 
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Taken together, these findings raise the question whether there is an interaction 
between Sall1 and Tgfb or downstream mediators of TGF-β signaling on a genetic 
level. Further investigations will be needed to identify potential interactions and 
regulatory sites that influence Sall1 expression. 
7.3 The role of Sall1 in microglia 
It has been shown for kidney and limb organogenesis that Sall1 is required for the 
correct tissue patterning and is involved in the co-ordination of inducer signals 
between different tissue compartments 85,86. Sall1 also seems to be involved in 
early steps of cortical neurogenesis by promoting proliferation of precursor cells 
over differentiation into intermediate progenitors 91. These functions of Sall1 might 
be related to its interaction with genes implicated in embryogenesis and 
pluripotency such as β-Catenin/Wnt or Nanog respectively 90. So far a short and 
rather abundant binding sequence has been described for Sall1 118,119, which can 
be found in the promoter region of many potentially ‘Sall1-regulated’ genes. 
However the direct binding of Sall1 to these genes and the functional 
consequences of such binding require further investigations. 
In the case of murine microglia it is clear that Sall1 is highly expressed yet its 
functions are largely unknown. We propose Sall1 to be a transcriptional master 
regulator of microglia identity by controlling their unique transcriptional profile and 
maintaining their non-reactive phenotype. Here we show that deletion of Sall1 in 
microglia results in their activation on a genomic as well as phenotypic level and 
leads to alterations in CNS homeostasis. Microglia have been shown to actively 
participate in adult neurogenesis by clearing excessively generated, apoptotic 
neurons 62. Here we show that the phagocytic activity of Sall1-deficient microglia is 
increased compared to controls. And that microglia specific deletion of Sall1 results 
in dysregulated hippocampal neurogenesis indicated by decreased numbers of 
differentiating neuroblasts. It is tempting to speculate about a potential link 
between increased phagocytosis of microglia and reduced number of neuroblasts, 
however more detailed studies will be needed to investigate this. Furthermore it 
would be interesting to address whether the observed changes in neurogenesis 
due to loss of Sall1 in microglia result in impaired memory formation and impact on 
cognitive and behavioral function as it has been proposed for other models 120. 
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Even though Sall1 is not essential for microglia development, as Sall1 knockout 
mice display similar microglia numbers to controls, the functional impact of this 
deletion during embryogenesis remains to be shown. Since Sall1 knockout mice 
die within the first 24h due to severe kidney dysgenesis or agenesis and given that 
neuronal precursors also depend on Sall1 during embryonic development, targeted 
deletion of Sall1 to individual CNS compartments will be required. Mouse strains 
like Vav1Cre or NestinCre could allow for a specific deletion of Sall1 in microglia vs. 
neurons and glial precursors respectively and provide insights into the individual 
contributions of each compartment to embryonic neurogenesis. 
7.4 Microglial contributions to CNS damage and inflammation 
In addition to their homeostatic functions, microglia have also been implicated in 
neurodegenerative diseases, CNS injury and aging related CNS alterations. The 
exact contributions of microglia to these processes however remain a matter of 
debate and current concepts attribute them beneficial as well as detrimental 
functions. In the case of EAE as a model of autoimmune demyelination, we could 
show that deletion of Sall1 in microglia leads to an increased number of infiltrating 
monocytes-derived cells at peak disease, while disease onset and clinical score do 
not differ at that time point. It has been suggested previously that microglia mostly 
release mediators that promote the encephalitogenic potential of autoreactive T 
cells, the infiltration and activation of inflammatory monocytes as well as the tissue 
destruction by ROS 67-71. It would be interesting to see if previous activation of 
microglia by the deletion of Sall1 affects their cytokine production, phagocytic 
activity and inflammatory response and if that in turn leads to alterations in disease 
progression and/or recovery. This is not only true for tissue destructive actions 
such as in models of EAE or ALS but also for tissue repair for example by 
clearance of Aβ plaques in AD and of cellular debris after injury. Furthermore, 
targeted modulation of microglia via the Sall1 locus offers a new route of 




7.5 Translation of the Sall1 specificity to human  
So far functional investigations and genetic profiling of different cell populations are 
mainly based on mouse models. First gene expression studies suggest that human 
microglia also express SALL1 121. To this day however there are no detailed 
datasets available comparing distinct human macrophage populations throughout 
different tissues obviating any claim of SALL1 specificity to human microglia similar 
to that of mice. One study providing gene expression profiling of human CNS cells 
with the focus on astrocytes suggested that other CNS resident cells might also 
express SALL1 121. However, so far this is the only data set of such kind and needs 
to be verified. We would therefore be reluctant to assign a specific gene expression 
to human microglia based on this data set only. In addition, transcription and 
translation are often not identical, due to post-transcriptional, translational, post-
translational and degradative modifications and protein data of human tissues is 
very sparse. Immunohistochemistry of human brain biopsies using a Sall1-specific 
antibody could address this question. To this day, based on the limited resources, 
the specificity of SALL1 expression in human myeloid cells and the CNS stroma 
remains to be shown. However it might very well be that there are species-specific 
differences in Sall1 expression.  
Collectively, the ability to target microglia and microglia function through Sall1 
allows for an unprecedented level of specificity. Moreover, the identification of Sall1 
as a microglia fate regulator will better enable us to identify the relevant biological 







8 Closing remarks 
Microglia-specific conditional gene-targeting has been a challenge for a long time 
and has hampered our progress in understanding the function of these CNS-
resident macrophages during development, health and disease. Here, by using 
Sall1CreER mice, we demonstrate microglia-specific targeting without targeting of 
other members of the MPS, wider hematopoietic system and adult CNS. We found 
Csf-1R signaling to be required for the survival of adult microglia. This has been 
suggested in the past but until now never conclusively been demonstrated. 
Likewise TGF-βR signaling has also been implicated for the development and 
maintenance of microglia 50. Yet, microglia-specific deletion of TGF-βR revealed its 
role in maintaining the homeostatic phenotype of adult microglia, but not their 
survival.  
Sall1 controls microglia fate by regulating their unique gene expression profile, 
allowing them to exert their ‘house-keeping’ functions critical for homeostasis of the 
adult CNS. We show that deletion of Sall1 in microglia specifically leads to a 
genetic as well as phenotypic activation of microglia that results in a disrupted CNS 
homeostasis as reflected by dysregulated neurogenesis. Taken together our data 
provide a new approach of specifically targeting microglia, allowing for detailed 
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9 Materials and Methods 
9.1 Mice and animal experiments 
Mice were housed in individually ventilated cages under specific pathogen-free 
conditions. Conventional C57BL/6 and C57BL/6-CD45.1 mice (wt) were purchased 
from Janvier Labs. Sall1CreER, Sall1fl/fl and Sall1GFP mice were described previously 
95,104,118,122. Cx3cr1CreER were kindly provided by Steffen Jung (Weizmann Institute 
of Science, Israel) 19. Csf1rfl/fl mice were kindly provided by Jeffrey Pollard (Albert 
Einstein College of Medicine, New York)123. Tgfbr2fl/fl, Cx3cr1GFP, iDTR, R26-yfp 
and R26-rfp mice were bred in-house 98,124,125. 
To perform embryo studies at a specific age, timed matings were set up: male and 
female mice were mated over night, and the day after was counted as embryonic 
day (E) 0.5. At the day of analysis pregnant females were euthanized by CO2 
inhalation, embryos were removed and euthanized by decapitation. 
Experimental autoimmune encephalomyelitis (EAE) was induced as described 
previously 126. Briefly, mice were immunized subcutaneously with 200 µg of 
MOG35-55 peptide (MEVGWYRSPFS-RVVHLYRNGK; GenScript) emulsified in 
CFA (Difco) in a total volume of 200 µl and two intraperitoneal injections of 200 ng 
Pertussis toxin (Sigma) on day 0 and 2. Clinical disease was scored as follows: 0, 
no detectable signs of EAE; 0.5, distal limp tail; 1, complete limp tail; 1.5, limp tail 
and hind limb weakness; 2, unilateral partial hind limb paralysis; 2.5, bilateral 
partial hind limb paralysis; 3, complete bilateral hind limb paralysis; 3.5, complete 
hind limb paralysis and unilateral forelimb paralysis; 4, total paralysis of fore and 
hind limbs (score ≥ 4, to be killed); 5, death.  
Bone marrow (BM) chimeras were generated as previously described 127. In brief, 
recipient mice were lethally irradiated with a split-dose of 2 x 550 rad about 15 h 
apart using a RS 2000 Biological Research X-ray Irradiator (Rad Source 
Technologies) and reconstituted i.v. with 2-5x106 BM cells isolated from the 
respective gender-matched donor mice. Mice were treated with 0.1% Borgal 
(Intervet) in drinking water for two weeks to prevent bacterial infections. 
Reconstitution of recipient mice was monitored by tail bleeding and flow cytometry 
at 6 weeks post transfer. 
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In order to enable Cre recombination in Tamoxifen-inducible CreER mouse strains, 
Tamoxifen (Sigma) was dissolved in corn oil to a concentration of 25 mg/ml and 
was administered i.p. (2.5 mg) or via o.g. (5 mg). Alternatively, mice were fed ad 
libitum with a diet containing 400 ppt tamoxifen citrate (Harlan) for 4 - 6 weeks. 
The small molecule kinase inhibitor PLX5622 to block Csf-1R signaling was 
provided by Plexxikon and was administered ad libitum via a diet containing 1,200 
mg/kg. 
For systemic inflammation via LPS treatment 100 µg LPS (Sigma) were 
administered i.p. and animals were euthanized 24 h after the injections.  
To induce targeted cell death in iDTR mouse strains 500 ng DTx (Sigma) were 
administered i.p. 
All animal experiments performed in this study were approved by the Swiss 
cantonal veterinary office (licenses 86/2012 and 100/2015).  
9.2 DNA isolation and genotyping 
Biopsies were collected from toe tips or ears of mice and lysed for approximately 1 
h at 95°C in 50mM NaOH solution. 1M TrisHCl pH 8.5 was added to neutralize the 
reaction. Samples were centrifuged at 10’000 rpm to pellet the remaining tissue 
debris and the supernatant was used for DNA analysis. 
For genotyping 1 µl of DNA template and 0.5 µl of each primer (10 µM, Thermo 
Fisher Scientific) was used in 1x Hot Fire Pol Blend master mix (Solis BioDyne). 
PCR amplification was performed on a C1000 Thermal Cycler (BioRad) as 
indicated below and PCR products were analyzed in a 1.5 % Agarose 
(Biocompare) gel containing GelRed (Biotium) for DNA visualization using the 
AlphaImager 2200 with the AlphaEaseFC software. 
 
  




Task Temperature (°C) Time (sec) Cycles 
initial denaturation 95 900 
denaturation 94 30 
35 annealing 58 45 
extention 72 60 
final extension 72 420 
 
List of primers and gene products: 
 
Gene Primer sequence (5’ to 3’) PCR product (bp) 
Sall1fl  
1: CCT CTG CCC GAG AGA TCG 
2: GGC GCG TCT GAT TTT ATT TC 





1: CAA CTT GCG ATT GCC ATA AA 
2: GCG TTG GCT ACC CGT GAT AT 





1: GCG GTC TGG CAG TAA AAA CTA TC 
2: GTG AAA CAG CAT TGC TGT CAC TT 
3: CTA GGC CAC AGA ATT GAA AGA TCT 




R26-rfp /  
R26-dtr 
1: AAG ACC GCG AAG AGT TTG TC 
2: AAA GTC GCT CTG AGT TGT TAT 
3: GGA GCG GGA GAA ATG GAT ATG 
wt: 600 
mut: 320 
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Csf1rfl 
1: ACC CAG AGC CCC CAC AGA TA 
2: GCC ACC ATG TGT CCG TGC TT 
wt: 445 
mut:  306 
Tgfbr2fl 
1: TAT GGA CTG GCT GCT TTT GTA TTC 
2: TGG GGA TAG AGG TAG AAA GAC ATA 
wt: 422 
mut:  575 
 
9.3 Leukocyte isolation from CNS 
Mice were sacrificed by CO2 inhalation and intracardially perfused with 
approximately 20 ml PBS. The brain was carefully removed from the skull and the 
spinal cord was flushed out by hydrostatic pressure. When indicated, choroid 
plexus was manually separated from the ventricle areas of the CNS using fine 
Dumont forceps (5) and a binocular. Brain and spinal cord were pooled and cut into 
small pieces using scissors, followed by a tissue digest in 0.4 mg/ml collagenase 
type IV (from Clostridium histolyticum, Sigma) in HBSS (containing Ca2+ / Mg2+, 
Invitrogen) supplemented with 10 % FCS (Biochrom AG) for 45-60 min at 37°C 
while agitating. Digested tissues were passed through an 18 G syringe and filtered 
through a 70µm cell strainer to obtain a homogeneous cell suspension. After 
washing, the cell suspension was further enriched using a 30 % Percoll (GE 
Healthcare) continuous gradient, centrifuged at 4°C for 30 min at 10’800 rpm with 
low brakes. The myelin in the upper Percoll layer was removed and the remaining 
cell suspension was washed and transferred into 1.5ml tubes for further analysis. 
9.4 Leukocyte isolation from other organs 
Mice were sacrificed by CO2 inhalation and intracardially perfused with 
approximately 20 ml PBS. Organs of interest were harvested, cut into small pieces 
and digested for 45 min at 37°C in collagenase solution as described above. 
Digested tissues were passed through an 18 G syringe and filtered through a 70µm 
cell strainer to obtain a homogeneous cell suspension. 
For blood, spleen and kidney, red blood cells were lysed in red blood cell lysis 
buffer (4.15 g NH4Cl, 0.55 g KHCO3, 0.185 g EDTA in 500 ml ddH2O) for 5 min at 
RT. Samples were washed with PBS before further processing. This step was 
repeated if necessary. 
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Liver samples were enriched in a continuous 30% Percoll gradient, centrifuged for 
30 minutes at 1700 rpm at room temperature without brakes. After fat and 
supernatant in the upper layers were removed, red blood cell lysis was performed 
on the pellet containing the leukocytes as described before. Cells were washed 
with PBS and filtered using a 70 µm cell strainer to obtain a single cell suspension.  
As skin samples ears were used, which were split into dorsal and ventral parts 
using forceps and incubated at 37°C for 90 min in 2.4 mg/ml of Dispase (Sigma) 
diluted in HBSS (containing Ca2+ / Mg2+, Invitrogen). Afterwards dermis and 
epidermis were separated and both were cut separately into small pieces and 
digested in collagenase solution as described above for 2 h. Cells were washed 
with PBS and filtered using a 70 µm cell strainer to obtain a single cell suspension. 
9.5 Flow cytometry and cell sorting 
Single cell suspensions were stained for 20-30 min at 4 °C in an appropriate 
amount of PBS or FACS buffer (PBS with 2 % FCS and 0.01 % NaN3). Before 
analysis the cells were washed once with PBS and filtered through a 70 µm cell 
strainer again. Flow cytometric analysis was performed using a FACSCanto II or 
LSRII Fortessa flow cytometer and FACSDiva software (BD Biosciences). Cell 
sorting was carried out using a FACSAria III (BD Biosciences) using an 85 µm 
nozzle, with a purity of >95 %. Data analysis was performed using FlowJo 9.9.x or 
10.0.x software (TreeStar). Fluorochrome-conjugated monoclonal antibodies (mAb) 
specific for mouse I-A/I-E (clone M5/114.15.2), CD11b (clone M1/70), CD11c 
(clone N418), CD45 (clone 30-F11), CD45.1 (clone A20), CD45.2 (clone 104), 
CD115 (clone AFS98), Ly6C (clone AL-21 or HK1.4), Ly6G (clone 1A8), Gr1 (clone 
RB6-8C4), Siglec-H (clone 551), CD3 (clone 17A2), CD45R (clone RA3-6B2), 
Siglec-1 (clone 3D6.112), CD64 (clone X54-5/7.1), Siglec-F (clone E50-2440), 
CD103 (clone 2E7), Ki67 (clone SOLA15), GLAST (clone ACSA-1), MOG (clone 8-
18c5), Lyve1 (clone ALY7), MerTK (clone DS5MMER), CD206 (clone MR5D3), 
CD31 (clone 390), EpCam (clone G8.8), CD4 (clone GK1.5) purchased either from 
BD Biosciences, eBioscience, or Biolegend. Anti-F4/80 (clone Cl:A3-1) mAb was 
purchased from AbD. Prior to detailed analysis cells were always gated on single, 
live cells using FSC and SSC, dead cells were excluded with the live/dead Fixable 
Materials and Methods 
88 
Aqua staining kit (life technologies). Staining for Ki67 was performed using Foxp3 
Staining Buffer Set (eBiosciences) according to the manufacturer’s protocol.  
9.6 t SNE dimensionality reduction  
A concatenated FCS file of single, live CNS cells (10’000 cells each) and 
separately isolated choroid plexus cells (ca 1’500 cells each) from 3 Sall1GFP/+ mice 
was created using FlowJo X and uploaded to cytobank 
(http://fluidigm.cytobank.org). t-SNE dimensionality reduction was calculated based 
on all surface markers in the staining panel, excluding GFP (Sall1). Different CNS-
resident populations were subsequently gated manually as shown in Figure 13a 
and overlayed onto the two-dimensional t-SNE map. Expression heat-maps of the 
respective surface markers and Sall1 (GFP) where overlayed onto the respective t-
SNE maps. 
9.7 RNA isolation and quantitative rt-PCR 
Cells of interest were sorted into 1.5 ml tubes and centrifuged at 5000 rpm for 10 
min at 4°C. Supernatant was discarded and the cell pellet was lysed in RLT plus 
buffer (Qiagen) supplemented with 1 % β-mercaptoethanol (Sigma). RNA isolation 
was performed using the RNeasy Micro Plus Kit (Qiagen) according to the 
manufacturer’s instructions. RNA concentration was estimated using a NanoDrop 
1000 spectrophotometer (Thermo Scientific). 
For first strand cDNA synthesis 10 µl RNA were added to a 10 µl reaction mix 
containing M-MLV reverse transcriptase (200 U, Invitrogen), dNTPs (0.5 mM, 
Invitrogen), First strand buffer (1x, Invitrogen), DTT (10 mM, Invitrogen), oligo (dt) 
primers (10 ng, PeproTech) and RNasin Plus RNase Inhibitor (Promega) 
recombinant ribonuclease inhibitor (40 U, Thermo Fischer Scientific). Sample-
reaction mix was incubated 10 min at RT, 50 min at 37°C for reverse transcription, 
and 15 min at 70°C to inactivate the transcriptase. cDNA was diluted in water 
depending on the starting amount of RNA.  
For quantitative real-time PCR 2.5 µl of cDNA template was mixed with 0.25 µl of 
the respective forward and reverse primers (indicated below), 3.25 µl H2O and 
6.25 µl iTaq Universal SYBR Green Supermix (BioRad). Each sample was 
measured in triplicates on a CFX384 Touch Real-Time PCR Detection System 
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(Bio-Rad). Cycle threshold (Ct) values of gene of interest were normalized to the 
house keeping gene RNA polymerase II (Pol2) and relative gene expression was 
plotted as 2-ΔCq.  
 
Gene Primer sequence (5’ to 3’) 
Sall1 
Fwd: CCC GTG AGC GGC TGA TGT TTG AG 
Rev: TGG GGC GAC TTG GTT GAC CCT 
Sall1 
Fwd: GAC ATC CCC AGT TCT GCT CC 
Rev: ACC TCG CCG CTA GAT CCT TC 
Csfr1 
Fwd: CGC CGA AGT GGG ATT CAA CG 
Rev: CAG CGT TGA GAC TGA GAG CC 
Tgfbr2 
Fwd: AAC GAC TTG ACC TGT TGC CTG T 
Rev: CTT CCG GGG CCA TGT ATC TT 
Il 1b 
Fwd: GAT CCA CAC TCT CCA GCT GCA 
Rev: CAA CCA ACA AGT GAT ATT CTC CAT G 
Tnfa 
Fwd: CAT CTT CTC AAA ATT CGA GTG ACA A 
Rev: TGG GAG TAG ACA AGG TAC AAC CC 
Cxcl10 
Fwd: CTG CCG TCA TTT TCT GCC TC 
Rev: CAC TGG CCC GTC ATC GAT AT 
Pol2 
Fwd: CTG GTC CTT CGA ATC CGC ATC 
Rev: GCT CGA TAC CCT GCA GGG TCA 
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9.8 Next generation sequencing 
For next generation sequencing (NGS) microglia of Sall1CreER/fl and control Sall1fl/fl 
mice were sorted and total RNA was isolated using the RNeasy micro plus kit 
(Qiagen). 2 ng RNA were amplified using the Ovation® Single Cell RNA-seq 
System kit (Nugen) according to the manufacturer’s protocol. NGS and 
bioinformatic analysis was performed by the Functional Genomics Center Zurich 
(FGCZ) using the HiSeq 2500 v4 System (Illumina). Quality control included fastqc 
and DESeq2 analysis. GO pathway analysis was performed using the MetaCore™ 
software (Thomson Reuters) and visualization was done using the MultiExperiment 
Viewer (TM4) and Prism (GraphPad). 
9.9 Immunohistochemistry 
Mice were euthanized with CO2 and intracardially perfused with approximately 20 
ml PBS. The CNS was carefully extracted and post-fixed in 4% paraformaldehyde 
(Kantonsaptheke, Morphisto) for 24 h. The samples were preserved in 30% 
sucrose (Sigma) solution in PBS for 24 - 48 h prior to embedding in OCT cryo 
embedding medium (Medite) on dry ice. Cryo-sections were stored at -80°C until 
further processing. For immunohistochemistry, cryo-embedded CNS samples were 
cut on a HYRAX C60 cryostat microtome at 14 µm for direct mounting on glass 
slides or at 40 µm for free-floating sections in a 24-well plate with 1ml PBS per well 
supplemented with 0.1% NaN3. 
Directly mounted samples were washed once with PBS to remove the remaining 
OCT medium. CNS samples were blocked for 1 h at RT with blocking buffer 
containing PBS, 10% normal goat serum (NGS, Thermo Fisher Scientific) or BSA 
(Sigma) and 0.5 % Triton-x100 (Sigma). The primary antibodies were diluted in 
PBS supplemented with 4 % NGS or BSA and 0.1% Triton-x100 as listed below 
and incubated for 2 h at RT or overnight at 4°C. After thorough washing with PBS, 
samples ere incubated with different fluorochrome-conjugated secondary 
antibodies (Invitrogen) directed against the host IgG. Samples were washed again 
and covered with mounting medium containing DAPI (Dianova). 
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Antigen Host species Company dilution (1 : x) 
Calbindin rabbit Abcam 200 
CD31 rabbit BD Biosciences 200 
DCX rabbit Cell Signaling 200 
F4/80 rat AbD Serotec 200 
GFAP rat Invitrogen 500 
GFAP mouse Sigma 500 
GFP rabbit Abcam 5000 
GFP chicken Aves Labs 500 
Iba-1 rabbit WAKO 500 
Ki67 rat eBioscience 200 
MBP mouse Millipore 300 
NeuN mouse Millipore 300 
Olig2 rabbit Sigma 500 
S100B rabbit Abcam 200 
 
Images were acquired on a Confocal Laser Scanning Microscope SP5 (Leica) and 
analysis was performed using the Imaris software (Bitplane) and Fiji (ImageJ, GNU 
General Public License). 
For 3D reconstruction, microglia were recorded with a 63x magnification and 3-
times zoom in Z stacks of 0.17µm steps in z direction, 512 × 512 pixel resolution. 
Images were analyzed using an Imaris-based automatic reconstruction (Bitplane). 
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9.10 Phagocytosis assay 
Primary microglial cells were isolated ex vivo from Sall1CreER/fl and control Sall1fl/fl 
mice as described above for leukocyte isolation from CNS. Cells were plated into a 
48-well plate with PBS supplemented with 5 % FCS and cultured for 4h with 
pHodro Red Zymosam Bioparticles (Thermo Fisher Scientific) at 37°C. As negative 
control cells were incubated with Cytochalasin D (Sigma) 30 min prior to the assay 
to block phagocytosis. For flow cytometric analysis, cells were detached using 
Accutase (Thermo Fisher Scientific), washed once with PBS and stained as 
described before. For immunohistochemistry, cells were directly plated on poly-L-
Lysine coated glass coverslips at the beginning of the assay, washed once with 
PBS and counter stained with Iba-1 as described before. Maximal 
excitation/emission of pHrodo Red was measured at 560/585 nm. 
9.11 Multiplex immunoassay 
For cytokine measurements, serum as well as CNS, spleen, kidney, liver and heart 
were isolated from Sall1CreER/fl and control Sall1fl/fl mice. For whole tissue lysates 
80-110 mg tissue were homogenized in Cell Lysis Buffer (Cell Signaling) using the 
a TissueLyser (Qiagen) for 2.5 min at 25 Hz. Samples were rested on ice for 30 
min, sonicated twice for 10 seconds at 35% maximal amplitude and centrifuged at 
12’000 rpm for 10 min. Supernatant was used for further analysis. GM-Csf, IFN-γ, 
IL-10, IL-12p70, IL-1β, IL-2 IL-6 and TNF-α were measured on a 8-plex 
electrochemiluminescence detection assay and read on the MSD QuickPlex SQ 
120 (both Meso Scale Discovery, Gaithersburg, MD). 
9.12 Statistical analysis 
Mean values, SEM values, and p-values were calculated and plotted with Prism 5 
software (GraphPad). Two-tailed unpaired t-test was performed to determine 
statistical significance between two groups. Welshʼs correction was applied in case 
of significantly different variances. For three or more groups one-way ANOVA with 
Dunnett or Bonferroni post test was performed. p-Values below 0.05 were 
considered significantly different (*P <0.05, **P < 0.01, ***P < 0.001). Data is 
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